

Draft Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action Plan

Summary

During an influenza pandemic, healthcare workers will be on the front lines delivering care to patients and preventing further spread of the disease. As the nation prepares for pandemic influenza, multiple avenues for protecting the health of the public are being carefully considered, ranging from rapid development of appropriate vaccines to quarantine plans should the need arise for their implementation. One vital aspect of pandemic influenza planning is the use of PPE—the respirators, gowns, gloves, face shields, eye protection, and other equipment that will be used by healthcare workers and others in their day-to-day patient care responsibilities.

However, efforts to appropriately protect healthcare workers from illness or from infecting their families and their patients are greatly hindered by the scarcity of data on the transmission of influenza and the challenges associated with training and equipping healthcare workers with effective personal protective equipment. Due to this lack of knowledge on influenza transmission, it is not possible at the present time to definitively inform healthcare workers about what PPE is critical and what level of protection this equipment will provide in a pandemic. The outbreaks of severe acute respiratory syndrome (SARS) in 2003 have underscored the importance of protecting healthcare workers from infectious agents. The surge capacity that will be required to reduce mortality from a pandemic cannot be met if healthcare workers are themselves ill or are absent due to concerns about PPE efficacy. The increased emphasis on healthcare PPE and the related challenges anticipated during an influenza pandemic necessitate prompt attention to ensure the safety and efficacy of PPE products and their use.

In 2006, the IOM COPPE determined that there is an urgent need to address the lack of preparedness regarding effective PPE for use in an influenza pandemic. Subsequently, the National Personal Protective Technology Laboratory (NPPTL) at the National Institute for Occupational Safety and Health (NIOSH) asked the Institute of Medicine (IOM) to examine issues regarding PPE for healthcare workers in the event of pandemic influenza. The IOM committee was charged with examining research directions, certification and the establishment of standards, and risk assessment issues specific to personal protective equipment for healthcare workers during an influenza pandemic.

The IOM provided three overarching conclusions and a series of recommendations for maximizing the opportunity to incorporate PPE into influenza pandemic research. The committee also provided recommendations regarding future research opportunities. The twelve recommendations made to address the three overarching conclusions are as follows:

Understand Influenza Transmission

- Initiate and Support a Global Influenza Research Network

Commit to Worker Safety and Appropriate Use of PPE

- Emphasize Appropriate PPE Use in Patient Care and in Healthcare Management, Accreditation, and Training
- Identify and Disseminate Best Practices for Improving PPE Compliance and Use

- 46 • Increase Research and Research Translation Efforts Relevant to PPE Compliance
47 *Innovate and Strengthen PPE Design, Testing, and Certification*
48 • Define Evidence-Based Performance Requirements (Prescriptive Standards) for PPE
49 • Adopt a Systems Approach to the Design and Development of PPE
50 • Increase Research on the Design and Engineering of the Next Generation of PPE
51 • Establish Measures to Assess and Compare the Effectiveness of PPE
52 • Ensure Balance and Transparency of Standards-Setting Processes
53 • Strengthen Pre-market Testing of PPE for Healthcare Workers
54 • Strengthen Post-market Evaluation of PPE for Healthcare Workers
55 • Coordinate Efforts and Expand Resources for Research and Approval of PPE
56

57 One of the challenges for the healthcare field is to clearly understand the differences between
58 respirators and medical masks as well as their appropriate uses. Medical masks (the term is used
59 in this report to encompass surgical masks and procedure masks) are loose-fitting coverings of
60 the nose and mouth designed to protect the patient from the cough or exhaled secretions of the
61 physician, nurse, or other healthcare worker. Medical masks are not designed or certified to
62 protect the wearer from exposure to airborne hazards. They may offer some limited, as yet
63 largely undefined, protection as a barrier to splashes and large droplets. However, because of the
64 loose-fitting design of medical masks and their lack of protective engineering, medical masks are
65 not considered personal protective equipment.
66

67 A terminology issue has further confused and blurred the boundary between medical masks and
68 respirators. The term respirator is used in the healthcare field to refer to two different medical
69 devices: (1) the personal protective equipment discussed in this report that is used to reduce the
70 wearer's risk of inhaling hazardous substances and (2) the mechanical ventilator device that is
71 used to maintain the patient's respiration following endotracheal intubation. This dual (medical
72 and occupational) use of the term respirator has prompted many healthcare workers to refer to
73 PPE respirators as masks, thereby confounding the important distinctions between medical
74 masks and respirators.
75

76 Protection of the healthcare worker against infectious disease can also involve gloves, eye
77 protection, face shields, gowns, and other protection. For the most part, these products are
78 designed to provide a barrier to microbial transfer with particular attention to protecting the
79 wearer's mucous membranes. The extent of liquid penetration is a major issue with gowns and
80 gloves. Comfort and wearability issues include the breathability of the fabric or material and
81 biocompatibility or sensitivity to avoid contact dermatitis and other skin irritations. Issues related
82 to viral survival on contaminated surfaces and objects, viral penetrance, and reusability remain to
83 be explored as do considerations about how best to integrate the use of the various types of
84 protective equipment to ensure that they integrate effectively (e.g., the respirator and eye
85 protection).
86

87 More than 14 million workers in the United States (approximately 10 percent of the U.S.
88 workforce) are employed in the healthcare field. Thus, it's important that we protect those
89 workers on the front lines with the best available PPE and prevention methods to handle an
90 influenza pandemic. To that end, it is imperative that a global influenza research network be

91 established to examine the influenza transmission issues that directly affect the PPT Program.
92 Some of the major questions that need answers are:

- 93
- 94 • What are the relevant sizes of aerosols?
 - 95 • What is the infectivity of aerosols?
 - 96 • Is high humidity an issue with wearing respirators?
 - 97 • How does air flow exchange and ventilation affect transmission?
 - 98 • and Should other than respirator PPE be certified, if so who's responsibility is it?
- 99

100 NIOSH/NPPTL has the overall management responsibility for the NIOSH PPT Program and is
101 responding to the IOM report by developing an action plan for addressing the issues and
102 recommendations within the PPT program domain described in the report. The action plan
103 provides both a near term and long term strategy for influenza pandemic research, development,
104 and investigative testing for the PPT Program. The action plan is structured to align with the
105 recommendations outlined in the IOM report, *Preparing for an Influenza Pandemic: PPE for*
106 *Healthcare Workers, 2008*. Each recommendation identifies current activities in progress within
107 the NIOSH PPT Program and subsequent activities which should be considered for both near
108 term and long term implementation. Associated references and weblinks are provided for
109 ongoing activities where available. Each text description is accompanied by a flow chart which
110 provides a pictorial representation of the information described in the associated text. Associated
111 Gantt Charts identifying anticipated timelines for conducting the activities in response to each
112 recommendation follow the flow charts. The PPT Program ongoing and potential future
113 activities are highlighted in yellow. The action plan addresses implementation of research
114 recommendations in the workplace. The following steps are being taken to develop the action
115 plan:

- 116 • Assess the IOM recommendations to identify actions within the PPT Program domain
 - 117 • Review on-going and proposed PPT Program activities
 - 118 • Assess the IOM recommendations to determine if existing data are available to make
119 decisions on whether the recommendations should be implemented near or long term
 - 120 • Apprise applicable organizations to disseminate actions outside the PPT Program
121 domain.
 - 122 • Solicit stakeholder input on action plan.
 - 123 • Review on-going activities in NIOSH, academia, government, and industry related to
124 influenza pandemic preparedness.
 - 125 • Prioritize activities in response to recommendations within the PPT Program domain
 - 126 • Determine if new initiatives for PPT Program should be managed through intra- or extra-
127 mural processes
 - 128 • Schedule project proposals into the PPT Program strategic planning process
 - 129 • Develop final PPE for HCW Action Plan
 - 130 • Implement PPE for HCW Action Plan
- 131

132 Being ready for an influenza pandemic—having the necessary resources to minimize morbidity
133 and mortality—is the goal of ongoing global efforts in many areas of endeavor. Since healthcare
134 workers are essential for providing patient care during a pandemic, the personal protective
135 equipment that can protect these workers from becoming infected or from transmitting infection

136 is a vital part of these efforts. Healthcare worker safety is essential for patient safety and patient
137 care. Being prepared for an influenza pandemic places a priority on protecting the healthcare
138 workforce.

139

140 I. Introduction

141

142 In 2005, the NIOSH NPPTL asked the IOM to form a standing committee to provide strategic
143 guidance in addressing Personal Protective Equipment issues for workers. One issue the
144 committee deemed of high importance is PPE for Healthcare Workers (HCW) in the event of
145 pandemic influenza. NPPTL then funded a 12 month study conducted by an adhoc IOM
146 committee. The IOM committee was charged with examining research directions, certification
147 and the establishment of standards, and risk assessment issues specific to PPE for healthcare
148 workers during an influenza pandemic.

149

150 The IOM completed the study and issued the report *Preparing for an Influenza Pandemic:
151 Personal Protective Equipment for Healthcare Workers* to the PPT Program in September 2007.
152 The IOM provided three overarching conclusions and a series of recommendations for
153 maximizing the opportunity to incorporate PPE into influenza pandemic research. The committee
154 also provided recommendations regarding future research opportunities. The three overarching
155 conclusions are stated here:

- 156 • Understanding influenza transmission—Current knowledge is rudimentary regarding the
157 mechanisms and routes of human-to-human influenza transmission (Chapter 2), but with
158 dedicated resources and new technologies, more can be known about the extent of
159 droplet, aerosol, and contact transmission and the optimum ways to prevent transmission.
- 160 • Making the commitment to worker safety and appropriate use of PPE—Healthcare
161 workers often do not wear the protective equipment needed to ensure that they are
162 adequately protected from exposure to hazardous agents including infectious disease.
163 Strengthening the commitment of healthcare employers to worker safety and enhancing
164 the culture of safety in the workplace involve both an organizational and an individual
165 commitment to the appropriate use of PPE (Chapter 4).
- 166 • Designing, testing, and certifying effective PPE for the healthcare workforce—Using
167 PPE in a healthcare workplace places specific demands on the design and engineering of
168 these products that are particularly focused on interactions with patients and ensuring that
169 healthcare workers do not become infected and do not transmit infection. An integrated
170 effort is needed to further understand the requirements of healthcare workers and to
171 develop innovative materials and technologies that can meet these needs (Chapter 3).
172 Issues regarding the responsibilities of federal agencies and organizations have to be
173 clarified. Further, increasing the use of the field testing in the pre-market phase and
174 conducting thorough post-marketing evaluations is vital to the development of effective
175 products (Chapter 5).

176

177 The IOM recommendations encompass a nationwide focus for the PPT program and applicable
178 government agencies, manufacturers, and the healthcare industry. The twelve recommendations
179 made to address the three overarching conclusions are as follows:

- 180 • Understanding influenza transmission

- 181 ○ IOM Recommendation #1: Initiate and support a global influenza research
182 network. The Department of Health and Human Services (DHHS), in
183 collaboration with U.S. and global partners through the World Health
184 Organization, should lead a multination, multicity, and multicenter focused
185 research effort to facilitate understanding of the transmission and prevention of
186 seasonal and pandemic influenza. A global research network of excellence should
187 be developed and implemented.
- 188 • Making the commitment to worker safety and appropriate use of PPE
- 189 ○ IOM Recommendation #6: Emphasize appropriate PPE use in patient care and in
190 healthcare management, accreditation, and training. Appropriate PPE use and
191 healthcare worker safety should be a priority for healthcare organizations and
192 healthcare workers, and in accreditation, regulatory policy, and training.
- 193 ○ IOM Recommendation #7: Identify and disseminate best practices for improving
194 PPE compliance and use. CDC and the Agency for Healthcare Research and
195 Quality (AHRQ) should support and evaluate demonstration projects on
196 improving PPE compliance and use. This effort would identify and disseminate
197 relevant best practices that are being used by hospitals and other healthcare
198 facilities.
- 199 ○ IOM Recommendation #8: Increase research and research translation efforts
200 relevant to PPE compliance. NIOSH, the National Institutes of Health (NIH),
201 AHRQ, and other relevant agencies and organizations should support research on
202 improving the human factors and behavioral issues related to ease and
203 effectiveness of PPE use for extended periods and in patient care-interactive work
204 environments.
- 205 • Designing, testing, and certifying effective PPE for the healthcare workforce
- 206 ○ IOM Recommendation #2: Define evidence-based performance requirements
207 (prescriptive standards) for PPE. NIOSH, through the National Personal
208 Protective Technology Laboratory (NPPTL), in collaboration with extramural
209 researchers, manufacturers, and regulatory agencies, should define a set of
210 evidence-based performance requirements or prescriptive standards for PPE to
211 facilitate their design and development that optimally balances the cost, comfort,
212 and degree of protection of PPE and enhances the compliance with their use in the
213 field.
- 214 ○ IOM Recommendation #3: Adopt a systems approach to the design and
215 development of PPE. NIOSH should promote a systems approach to the design,
216 development, testing, and certification of PPE using evidence-based performance
217 requirements or prescriptive standards and fostering closer collaboration between
218 the users, manufacturers, and research and regulatory agencies.
- 219 ○ IOM Recommendation #4: Increase research on the design and engineering of the
220 next generation of PPE. NIOSH, the Department of Homeland Security, the
221 Department of Defense, manufacturers, and other relevant organizations and
222 agencies should fund research directed at the design and development of the next
223 generation of respirators, gowns, gloves, and eye protection for healthcare
224 workers that would enhance their safety and comfort.
- 225 ○ IOM Recommendation #5: Establish measures to assess and compare the
226 effectiveness of PPE. NIOSH, through NPPTL, should develop and promote a

- 227 validated set of measures for comparing the effectiveness of PPE products. The
228 goal is a set of measures that would allow users to compare and select appropriate
229 PPE commensurate with the assessed risk and desired level of protection.
230 Particular attention should be paid to disseminating information to healthcare
231 workers on PPE effectiveness relevant to influenza.
- 232 ○ IOM Recommendation #9: Ensure balance and transparency of standards-setting
233 processes. Federal agencies (e.g., FDA, NIOSH, OSHA) should use standards
234 developed through a consensus-based transparent process that sets specific and
235 clearly-defined limits regarding conflicts of interest (financial or other) and
236 involves broad representation of all affected parties.
 - 237 ○ IOM Recommendation #10: Strengthen pre-market testing of PPE for healthcare
238 workers. FDA, NIOSH, and other relevant agencies and organizations should
239 strengthen pre-market testing requirements for healthcare PPE by requiring field
240 testing of PPE prior to approval and by reevaluating the FDA medical device
241 classification for healthcare PPE. Testing requirements should use rigorous
242 standards while also providing expeditious review of innovative approaches.
 - 243 ○ IOM Recommendation #11: Strengthen post-market evaluation of PPE for
244 healthcare workers. NIOSH, FDA, and other relevant agencies and organizations
245 should support and strengthen adverse event reporting and post-market evaluation
246 studies and surveillance regarding the effectiveness of PPE used by healthcare
247 workers.
 - 248 ○ IOM Recommendation #12: Coordinate efforts and expand resources for research
249 and approval of PPE. Congress should expand the resources provided to NIOSH
250 to further research efforts on the next generation of PPE and to coordinate and
251 expedite the approval of effective PPE. Efforts to coordinate PPE testing,
252 certification, and approval across all relevant federal agencies should include
253 developing evidence-based performance standards for all types of PPE for
254 healthcare workers.

255 Additional issues the IOM committee identified as needing to be addressed are:

- 256 ● Substantial gaps in knowledge regarding the design and implementation of PPE for
257 family members and others during an influenza pandemic
- 258 ● Challenges include the benefits of minimizing or negating fit testing of respirators,
259 protecting people with a wide range of face sizes (including children), protecting people
260 with respiratory impairment.
- 261 ● Limited oversight of PPE sold in the retail marketplace.

263 NIOSH/NPPTL has the overall management responsibility for the NIOSH PPT Program and is
264 responding to the IOM report by developing an action plan for addressing the issues and
265 recommendations within the PPT program domain described in the report. The action plan
266 provides both a near term and long term strategy for influenza pandemic research, development,
267 and investigative testing for the PPT Program. The action plan is structured to align with the
268 recommendations outlined in the IOM report, *Preparing for an Influenza Pandemic: PPE for
269 Healthcare Workers, 2008*. Each recommendation identifies current activities in progress within
270 the NIOSH PPT Program and subsequent activities which should be considered for both near
271 term and long term implementation. Associated references and weblinks are provided for
272 ongoing activities where available. Each text description is accompanied by a flow chart which

273 provides a pictorial representation of the information described in the associated text. Associated
274 Gantt Charts identifying anticipated timelines for conducting the activities in response to each
275 recommendation follow the flow charts. The PPT Program ongoing and potential future
276 activities are highlighted in yellow. The action plan addresses implementation of research
277 recommendations in the workplace. The following steps are being taken to develop the action
278 plan:

- 279 • Assess the IOM recommendations to identify actions within the PPT Program domain
- 280 • Review on-going and proposed PPT Program activities
- 281 • Assess the IOM recommendations to determine if existing data are available to make
282 decisions on whether the recommendations should be implemented near or long term
- 283 • Apprise applicable organizations to disseminate actions outside the PPT Program
284 domain. **Activities annotated with ** in the action plan are outside the PPT
285 Program domain.**
- 286 • Solicit stakeholder input on action plan.
- 287 • Review on-going activities in NIOSH, academia, government, and industry related to
288 influenza pandemic preparedness.
- 289 • Prioritize activities in response to recommendations within the PPT Program domain
- 290 • Determine if new initiatives for PPT Program should be managed through intra- or extra-
291 mural processes
- 292 • Schedule project proposals into the PPT Program strategic planning process
- 293 • Develop final PPE for HCW Action Plan
- 294 • Implement PPE for HCW Action Plan
- 295

296 The next two sections describe: (1) the PPT Program assessment of the projects and activities
297 which would fulfill the IOM recommendations, i.e., detailed point by point response to each
298 IOM recommendation; and (2) PPE for HCW Action Plan, i.e., prioritized 10-year plan for a
299 sequence of activities to address recommendations.

300

301 The proposed timeline to finalize the action plan is described as follows:

- 302 • Draft action plan posted to NPPTL website (February 2008)
- 303 • Present plan at stakeholder meeting (March 2008)
- 304 • Open docket to solicit comments (February 2008 – April 2008)
- 305 • Revise action plan based on comments received (May 2008)
- 306 • Propose new projects as part of PPT Program strategic planning for FY09 and beyond
307 (June 2008)
- 308 • Revise action plan based on strategic planning decisions and project outputs (August
309 2008).
- 310 • Implement action plan
- 311

311

312 The final HCW Action Plan will be used to prioritize and select future PPT Program initiatives
313 including funding, staffing, and upgrading laboratory capabilities. As noted previously,
314 activities annotated with ** are outside the PPT Program domain.

315

316 **II. Assessment of Projects and Activities that align with the IOM Recommendations and** 317 **Additional Issues**

318

319 IOM Recommendation # 1: Initiate and Support a Global Influenza Research Network (Chap 2,
320 p 68)

321

322 The Department of Health and Human Services (DHHS), in collaboration with U.S. and global
323 partners through the World Health Organization, should lead a multination, multicity, and
324 multicenter focused research effort to facilitate understanding of the transmission and prevention
325 of seasonal and pandemic influenza. A global research network of excellence should be
326 developed and implemented.

327

328 ***PPT Program Plan in response to IOM Recommendation # 1***

329 1.1 Global Influenza Research Network

330 1.1.1 ** The near and long term opportunities for strong collaborative relationships are
331 found at many organizational levels, including:

- 332 • Within DHHS. DHHS is the parent agency of the Centers for Disease Control and
333 Prevention (CDC) which includes the National Institute for Occupational Safety and
334 Health (NIOSH) and six Coordinating Centers/Offices. The Food and Drug
335 Administration (FDA) and the National Institutes of Health (NIH) also are located in
336 DHHS. Within NIH, National Institute of Allergy and Infectious Diseases (NIAID)
337 plays the lead role in influenza research. CDC is the lead U.S. agency for public
338 health response and disease surveillance; CDC also carries out research in influenza
339 epidemiology and molecular virology, and conducts development activities for
340 vaccines and diagnostic tests. Within NIOSH, NPPTL has the specialized expertise
341 relevant to PPE. FDA regulates medical devices, vaccines, and therapies, and its
342 Center for Biologics Evaluation and Research conducts influenza research.
- 343 • Across Federal Agencies. Several agencies across the Federal government are
344 involved in activities relevant to influenza research, including the U.S. Department of
345 Agriculture (USDA), the Department of the Interior, the Department of Defense
346 (DoD), the Department of State, and the U.S. Agency for International Development
347 (USAID).
- 348 • With Private Industry. Both established pharmaceutical corporations and new start-up
349 companies play a vital role in the development of new products and strategies for
350 control of influenza. Efficient development of improved vaccines, therapeutics, and
351 diagnostics therefore requires close collaboration with the private sector.
- 352 • Internationally. The World Health Organization (WHO) is responsible for
353 coordinating global influenza surveillance and the global response to an emerging
354 influenza pandemic. DHHS is the official point of contact between WHO and the
355 U.S. government; CDC is a designated WHO Influenza Reference Center and thus
356 has the most extensive relationship with the WHO influenza program.

357

358 1.2 Identify and prioritize research questions with suggested possible study designs

359 1.2.1 Can infection take place through mucous membranes or conjunctiva exposure?

360 1.2.1.1 ** Near term research is needed to determine the appropriate levels of
361 protection for all viable routes of transmission.

362 1.2.2 What is role of UV light, humidity, temperature, pressure differentials, air flow and
363 exchange, and ventilation in preventing transmission?

- 364 1.2.2.1 Role of these environmental parameters on the effectiveness of PPE is long term
365 research.
- 366 1.2.2.2 ** Research is needed on the effectiveness of engineering control components
367 to regulate these environmental parameters.
- 368 1.2.2.3 NIOSH Division of Applied Research and Technology (DART) is exploring
369 isolation controls for biological agents. The current initiative is “Expedient
370 Patient Isolation for Bioterrorism and Epidemic Response”. This project seeks
371 to identify and provide detailed implementation guidance on expedient patient
372 isolation techniques that are affordable, easily implemented, provide effective
373 isolation, reduce potential healthcare worker exposures and do not interfere with
374 hands-on healthcare activities.
- 375 1.2.2.4 NIOSH DART is exploring isolation controls for biological agents. Another
376 ongoing initiative is “Expedient Airborne Isolation for Emergency Response
377 Exercises”. This research will attempt to translate knowledge learned from
378 prior research on expedient isolation within healthcare environments to non-
379 traditional “infectious” mass casualty environments such as that which might be
380 established in a cafeteria, gymnasium, or other shelter.
- 381 1.2.3 Do some fomites inactivate the virus and, if so, how rapidly?
- 382 1.2.3.1 NIOSH PPT Program is exploring decontamination of respirators. Current
383 initiatives available here: Reference [A](#).
- 384 Concerns over the unavailability, or decreased availability, of filtering facepiece
385 respirators in planning exercises of a pandemic influenza have raised the
386 question of the possibility of re-use of these respirators following
387 decontamination. Because little data exist on this very important issue, the PPT
388 Program has undertaken a research study looking at the effects of various
389 methods of decontamination (e.g., chemical, soap & water, UV light, gas
390 sterilization, microwaving, heat [e.g., autoclaving]) upon the filtration
391 performance of filtering facepiece respirators. The data have served to identify
392 some methods of decontamination (UV light, hydrogen peroxide) that do not
393 affect filtration performance and could potentially be useful, whereas others
394 (bleach, ethylene oxide, microwave) degrade the respirator somewhat (but not
395 enough to cause filtration performance to drop below NIOSH certification
396 standards), and others (isopropyl alcohol, soap & water, and autoclaving)
397 excessively degrade the performance or deform the respirator. This work will
398 also allow for the development of a standardized test protocol for measuring the
399 sterilization efficacy of a decontamination procedure for filter medial and
400 filtering facepiece respirators.
- 401 1.2.3.2 ** Long term research is needed to determine conditions and materials that do
402 not support long-term survivability and viability.
- 403 1.2.4 What should the public health messages be with regard to preventing transmission
404 (e.g., open windows, use hand sanitizers)?
- 405 1.2.4.1 PPT Program continues to conduct research and provide recommendations for
406 the prudent use of PPE based on the best available knowledge.
- 407 1.2.4.2 NIOSH/Division of Surveillance, Hazard Evaluations and Field Studies
408 (DSHEFS) has capabilities to provide guidance and assistance to employers and
409 workers, including healthcare workers, addressing workplace hazards associated

- 410 with pandemic influenza and aerobiological contaminants as a part of HHS
411 pandemic influenza response plan responsibilities.
- 412 1.2.4.3 NIOSH/DSHEFS has developed a proposal for active surveillance of healthcare
413 facilities that would assemble information relevant to a number of issues
414 pertinent to the spread and preventive practices of influenza. Information
415 identified for collection includes use of respirators, infection control practices,
416 rates of infection, and infection patterns that may distinguish different types of
417 healthcare workers. This would also have the potential to relate influenza
418 infection patterns to various circumstances and work practices that may
419 contribute to infection.
- 420 1.2.4.4 ** Long term research is needed to better define viable routes of infection and
421 virulence, conditions that support transmissibility and conditions that support
422 long-term survivability and viability.
- 423 1.3 Provide priority funding to support near-term (1 to 3 years) laboratory and clinical studies
424 of influenza transmission and prevention of seasonal influenza with particular focus on the
425 effectiveness of types of PPE
- 426 1.3.1 ** Possible funding sources – CDC pandemic funds, NIH/NIAID
- 427 1.3.2 ** What are the major modes of transmission? How much does each mode of
428 transmission contribute individually or with other methods of transmission?
- 429 1.3.2.1 ** CDC/Office of the Director/Office of Strategy and Innovation
430 (CDC/OD/OSI)
- 431 1.3.2.2 New NIH Centers of Excellence identified in FY07 may be appropriate to
432 conduct studies.
- 433 1.3.2.3 Potential for Office of Extramural Programs (OEP) to provide grants for studies
434 related to transmission.
- 435 1.3.2.4 Results of this work are needed for PPT recommendations and serve as input to
436 PPT Program strategic planning (research, policy, etc).
- 437 1.3.3 What is the size distribution of particles expelled by infectious individuals, and how
438 does that continuum of sizes affect transmission?
- 439 1.3.3.1 NIOSH PPT Program has a NORA project to characterize the particle sizes,
440 quantity and size distribution of particles produced and expelled by coughing,
441 the dissemination of cough-generated aerosols in the environment, and the
442 effectiveness of disposable masks and respirators at preventing the release of
443 cough-generated particles. Based on results, NIOSH will be proceeding to
444 assess the affect of wearing respiratory protection when coughing and when in
445 the presence of someone coughing. This work is summarized here [Reference
446 [B](#)]. FY07 intramural program funding was \$269K. Results for this effort will
447 also feed into Recommendation 1 (1.3.6).
- 448 1.3.3.2 ** Research on the transmission and viability of unfiltered particles is needed.
- 449 1.3.4 Is the virus viable and infectious on fomites and for how long? Are fomites a means
450 of transmission and are some more able to transmit than others (i.e., viruses on
451 respirators or cloth versus metal or wood surfaces)?
- 452 1.3.4.1 Assess viability of virus on respirators.
453 Although respirators serve to protect the wearer, concerns exist that viruses
454 remaining on a respirator transform it into a fomite that may serve as a vehicle
455 for infection of the wearer, or others, through handling or reaerosolization.

456 Utilizing the MS-2 viral E-coli bacteriophage as an influenza surrogate, the
457 NIOSH PPT Program has undertaken a study addressing the viability of the
458 MS-2 virus on various models of filtering facepiece respirators (including
459 respirators with antimicrobial components). Samples of 2.5x2.5 cm² pieces of
460 respirator filter material exposed to MS2 particles are stored for various times
461 under optimal growth conditions. Since temperature is a major determinant for
462 MS2 survival, samples are stored at 22°, 30°, and 37°C. After incubation for 4
463 hrs, 1, 2, 4 and 7 days, the samples are processed and the percentage of MS-2
464 survival is calculated. Data generated by this study will offer important
465 information on fomite-related issues and also allow for the quantification of
466 subsequent decontamination effects on the respirator. This work is summarized
467 here: Reference [A](#).

468 1.3.4.2 ** Research on the transmissibility and viability (infectivity) of viruses is
469 needed to quantify the level and type of controls required to protect HCW from
470 potential fomite exposures.

471 1.3.4.2.1 CDC/National Center for Preparedness, Detection and Control of
472 Infectious Diseases (CDC/NCPDCID) and NIAID will be apprised of the
473 research needs.

474 1.3.4.2.2 ** PPE effectiveness study will examine survival rate of the live
475 vaccine/virus on internal and external surfaces of the PPE as described in
476 Reference [V](#).

477 1.3.4.2.2 These needs may be achievable under NIAID grants.

478 1.3.4.3 ** Research on the viability of viruses on materials and surfaces used for PPE
479 other than respirators and their ability to be decontaminated is needed.

480 1.3.4.3.1 CDC and NIAID will be apprised of the research needs.

481 1.3.4.3.2 These needs may be achievable under NIAID grants.

482 1.3.5 What activities in the healthcare setting are associated with minimal or increased
483 transmission?

484 1.3.5.1 ** Research studies, including surveillance and activity definitions, are needed
485 to define risk levels of workplace activities and locations for influenza
486 transmission in healthcare settings. These present both near and long term
487 opportunities.

488 1.3.5.2 NIOSH/Health Effects Lab Division (HELD) and Division of Respiratory
489 Disease Studies (DRDS) are working in collaboration with researchers at West
490 Virginia University on a project to examine the potential for airborne
491 transmission of influenza virus in a hospital emergency department. The
492 objective of the study is to better understand the mechanisms by which
493 influenza may be transmitted from infected patients to healthcare workers and
494 others in a healthcare facility. Selected workers in a local hospital emergency
495 department will wear a two-stage bioaerosol sampler during their normal work
496 routine to determine whether airborne influenza virus is detected during the
497 months of high influenza activity. The samplers will also be deployed in fixed
498 locations for area sampling. Since the sampler fractionates the aerosol particles
499 by size, the particle size information will help to determine if the virus is
500 transported in larger droplets and/or smaller droplet nuclei. Collected samples
501 will be evaluated for the presence of influenza virus by a PCR-based virus

502 detection system. Results will be analyzed by particle size to deduce by which
503 mechanisms the aerosolized virus may be transmitted, e.g. by (i) large droplet
504 contact, and/or (ii) small droplet nuclei in circulating air.

505 1.3.6 In light of the information that is gained on influenza transmission:

506 1.3.6.1 How effective is each type of PPE (gowns, gloves, respirators, etc.) in reducing
507 the risk of influenza transmission (quantitative performance analysis)?

508 1.3.6.1.1 An assessment of current standards needs to be conducted to categorize
509 existing PPE as it relates to current standards. NPPTL currently certifies
510 performance of respirators, other PPE performance is assessed by third
511 party certification authorities in accordance with consensus standards' test
512 methods. The PPT Program has limited infrastructure for PPT testing
513 beyond respirator issues. The PPT Program is planning to expand its
514 capability in protective clothing testing through training, additional
515 personnel, and cooperative efforts with third party certification authorities
516 and laboratories.

517 1.3.6.1.2 Respirator users cough study. Construction of a cough aerosol exposure
518 simulation system will enable measurement of how well surgical masks
519 and disposable filtering facepiece respirators protect healthcare workers
520 from potentially infectious aerosols produced by patients during coughing,
521 and to provide healthcare recommendations based upon the research
522 results. A cough simulator will be built that "coughs" a simulated aerosol-
523 laden cough through a standard head form (called the coughing head
524 form). A second head form (called the breathing head form) will be
525 connected to a breathing machine to simulate the inhalation and exhalation
526 of a healthcare worker; this second head form can be outfitted with a
527 surgical mask or respirator. The coughing and breathing head forms will
528 be placed in a test chamber to simulate the cough of a patient and the
529 respiration of a healthcare worker, and measure the amount of the cough
530 aerosol that is inhaled by the breathing head form with or without a
531 surgical mask or respirator. Five surgical masks and five respirators
532 corresponding to those in the CDC Strategic National Stockpile, which
533 could potentially be used to support healthcare operations in the event of a
534 pandemic, will be tested in this project. Current initiatives are described
535 in Reference [B](#).

536 1.3.6.1.3 Funding to develop appropriate surveillance initiatives is needed. The goal
537 of surveillance within the PPT Program will be to develop and strengthen
538 the use of surveillance data to identify priorities, trends, and emerging
539 issues associated with the use of PPE/PPT in the workplace. Information
540 gathered through the surveillance program will be used to provide baseline
541 data on PPE/PPT use in workplaces, develop outcome measures for other
542 NIOSH programs, help sharpen the focus of NPPTL's research program,
543 as well as aid in the development of a more effective and active
544 information dissemination program. The surveillance plan activities
545 applicable to this action plan include: analysis and linking of existing
546 databases, initial demonstration/pilot studies, and development of a
547 sentinel system for healthcare. The aim of the Sentinel System for

548 Healthcare is to develop an ongoing Demonstration and Sentinel
549 Surveillance System for the ongoing monitoring of PPE/PPT (N-95,
550 EUAE (Emergency Use Authorization Equipment) etc) selection, usage,
551 fitting, periodicity and effectiveness in five major hospitals in the United
552 States to evaluate and enhance timely interventional response to Pandemic
553 Influenza, Bioterrorism and other Disasters (natural and man-made). A
554 proposal for this work is under development.

555 1.3.6.2 How effective are medical masks?

556 1.3.6.2.1 ** Currently, performance is assessed in accordance with consensus
557 standards' test methods as FDA cleared medical devices.

558 1.3.6.2.2 Cough project will evaluate surgical masks as described in Reference [B](#).
559 Also, see write-up in 1.3.3.1 for details of this project.

560 1.3.6.2.3 ** Elastic textile solution pilot for prototype masks will examine masks
561 for potential protection against infectious aerosols as described in
562 Reference [U](#).

563 1.3.6.2.4 Funding to develop appropriate surveillance initiatives is needed.

564 1.3.6.3 What innovations regarding PPE are needed to enhance effectiveness?

565 1.3.6.3.1 NIOSH conducted workshops with RAND Jan 2004 to identify future PPE
566 needs.

567 1.3.6.3.2 Nov 30 - Dec 1 2004 PPT Program conducted workshop to assess current
568 state of knowledge of infectivity of bioaerosol: Workshop minutes are
569 provided in Reference [C](#).

570 1.3.6.3.3 PPT Program will conduct a workshop in 2008 to assess the current state
571 of technology. A commerce business daily presolicitation for a contractor
572 to coordinate and conduct the workshop was published on Nov 8, 2007.
573 [Reference [D](#)]

574 1.3.6.3.4 ** PPE Effectiveness Study will provide scientific evidence of the
575 efficacy of PPE (e.g. masks, respirators, eye protection) in reducing
576 airborne transmission of influenza as described in Reference [V](#).

577 1.4 ** Develop rigorous evidence-based research protocols and implementation plans for
578 clinical studies during an influenza pandemic.

579 1.4.1 Apprise CDC/NCPDCID of research needs and recommendations.

580 1.4.2 What percentage of patients aerosolize influenza virus during an infection?

581 1.4.2.1 ** Long term research.

582 1.4.3 How distinct is transmission in different venues including healthcare, schools, and
583 households?

584 1.4.3.1 ** Long term research.

585 1.4.4 What is the time sequence of infectivity?

586 1.4.4.1 ** Long term research.

587 1.4.5 If a person excretes virus during the presymptomatic period, is the individual
588 infectious; is virus found in the exhaled air during normal breathing or if someone has
589 a normal cough or sneeze (i.e., allergic cause)?

590 1.4.5.1 ** Long term research.

591 1.4.6 When patients receive antiviral drugs do they continue to excrete virus?


592 1.4.6.1 ** Long term research.

- 593 1.4.7 What is the virus concentration in saliva and nasal fluids when a person is
- 594 asymptomatic, during infection, and during recovery?
- 595 1.4.7.1 ** Long term research.
- 596 1.4.8 What is the impact of masking patients on transmission risk? If effective, how long
- 597 should a medical mask be worn?
- 598 1.4.8.1 ** Long term research.
- 599 1.4.8.2 ** Funding to develop appropriate surveillance initiatives is needed.
- 600 1.4.8.3 Cough project will evaluate surgical masks as described in Reference [B](#). Also,
- 601 see write-up in 1.3.3.1 for details of this project.
- 602

PPT Program PPE for HCW Action plan

603
604
605 *** For the recommendation charts below:

606 Objects with yellow fill represent NPPTL



607
608
609
610
611 Objects with orange fill represent NIOSH




612
613
614
615 Objects with light purple fill represent CDC



616
617
618 Objects with light green fill represent connectivity with other recommendations



619
620



625 IOM Recommendation # 2: Define Evidence-Based Performance Requirements (Prescriptive
626 Standards) for PPE (Chap 3, p 106)

627
628 NIOSH, through the National Personal Protective Technology Laboratory (NPPTL), in
629 collaboration with extramural researchers, manufacturers, and regulatory agencies, should define
630 a set of evidence-based performance requirements or prescriptive standards for PPE to facilitate
631 their design and development that optimally balances the cost, comfort, and degree of protection
632 of PPE and enhances the compliance with their use in the field.

633

634 ***PPT Program Plan in response to IOM Recommendation # 2***

635 2.1 Functionality – Protect against influenza virus, Guard against contact with contaminated
636 fluids and aerosols.

637 2.1.1 Develop standards for respiratory PPE.

638 2.1.1.1 Identify approaches to address gaps.

639 2.1.1.1.1 An assessment of current standards needs to be conducted to categorize
640 existing PPE as it relates to current standards. NPPTL currently certifies
641 performance of respirators, other PPE performance is assessed by third
642 party certification authorities in accordance with consensus standards' test
643 methods. The PPT Program has limited infrastructure for PPT research,
644 development and investigative testing beyond respirator issues. The PPT
645 Program is planning to expand its capability in protective clothing
646 research, development and investigative testing through training,
647 additional personnel, and cooperative efforts with third party certification
648 authorities and laboratories.

649 2.1.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR
650 Part 84. NPPTL has increased its capacity for Part 84 testing of N95
651 respirators from 2 particulate filter penetration test instruments to 3 test
652 instruments and a fourth instrument available as a backup or additional
653 capacity.

654 2.1.1.1.3 Collaboration with Users/Other Agencies and the PPT Program.

655 2.1.1.1.3.1 NPPTL has a program in place with FDA to certify penetration
656 characteristics for respirators to be designated as “Public Use
657 Respirator for Pandemic Flu” by the FDA. Two filtering facepieces
658 from one manufacturer are currently certified by FDA. PPT Program
659 has an additional program in place with FDA for manufacturers
660 seeking to make an antimicrobial claim on their FF products. PPT
661 Program handles the particulate testing and performance evaluation,
662 FDA makes the antimicrobial efficiency and safety determinations.

663 2.1.1.1.3.2 The PPT Program continues to collaborate with Occupational Safety
664 and Health Administration (OSHA) for coordination and support for
665 respirator selection and use requirements during emergency as well as
666 routine applications.

667 2.1.2 Develop standards for other than respirators.

668 2.1.2.1 Identify approaches to address gaps.

669 2.1.2.1.1 An assessment of current standards needs to be conducted to categorize
670 existing PPE as it relates to current standards. NPPTL currently certifies

- 671 performance of respirators, other PPE performance is assessed by third
672 party certification authorities in accordance with consensus standards' test
673 methods. The PPT Program has limited infrastructure for PPT research,
674 development and investigative testing beyond respirator issues. The PPT
675 Program is planning to expand its capability in protective clothing
676 research, development and investigative testing through training,
677 additional personnel, and cooperative efforts with third party certification
678 authorities and laboratories.
- 679 2.1.2.1.2 Other PPE performance is assessed by third party certification authorities
680 in accordance with consensus standards' test methods.
- 681 2.1.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.
- 682 2.2 Usability – Maintain biomechanical efficiency and sense of touch and feel, odor-free,
683 hypoallergenic, accommodate wide range of users (face and body profiles), compatibility
684 across various elements of the PPE ensemble and with other equipment (e.g., stethoscope),
685 non-startling to patients and families, facilitates communication with others (verbal, facial).
- 686 2.2.1 Develop standards for respiratory PPE.
- 687 2.2.1.1 Identify approaches to address gaps.
- 688 2.2.1.1.1 An assessment of current standards needs to be conducted to categorize
689 existing PPE as it relates to current standards. NPPTL currently certifies
690 performance of respirators, other PPE performance is assessed by third
691 party certification authorities in accordance with consensus standards' test
692 methods. The PPT Program has limited infrastructure for PPT research,
693 development and investigative testing beyond respirator issues. The PPT
694 Program is planning to expand its capability in protective clothing
695 research, development and investigative testing through training,
696 additional personnel, and cooperative efforts with third party certification
697 authorities and laboratories.
- 698 2.2.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR
699 Part 84.
- 700 2.2.1.1.3 Collaboration between ISEA and the PPT Program.
- 701 2.2.1.1.3.1 PPT Program anthropometric initiatives ongoing. [References [Q](#) &
702 [R](#)]
- 703 2.2.2 Develop standards for other than respirators.
- 704 2.2.2.1 Identify approaches to address gaps.
- 705 2.2.2.1.1 An assessment of current standards needs to be conducted to categorize
706 existing PPE as it relates to current standards. NPPTL currently certifies
707 performance of respirators, other PPE performance is assessed by third
708 party certification authorities in accordance with consensus standards' test
709 methods. The PPT Program has limited infrastructure for PPT research,
710 development and investigative testing beyond respirator issues. The PPT
711 Program is planning to expand its capability in protective clothing
712 research, development and investigative testing through training,
713 additional personnel, and cooperative efforts with third party certification
714 authorities and laboratories.
- 715 2.2.2.1.2 Other PPE performance is assessed by third party certification authorities
716 in accordance with consensus standards' test methods

- 717 2.2.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.
- 718 2.2.2.1.4 DSR input for whole body anthropometrics. [References [T](#)]
- 719 2.3 Comfort and Wearability – Comfortable—no skin irritation or pressure points,
720 Breathable—air, prolonged use without discomfort permeable, Moisture absorbent—
721 wickability, Low bulk and weight, dimensional stability, easy to put on and take off (don
722 and doff).
- 723 2.3.1 Develop standards for respiratory PPE.
- 724 2.3.1.1 Identify approaches to address gaps.
- 725 2.3.1.1.1 An assessment of current standards needs to be conducted to categorize
726 existing PPE as it relates to current standards. NPPTL currently certifies
727 performance of respirators, other PPE performance is assessed by third
728 party certification authorities in accordance with consensus standards’ test
729 methods. The PPT Program has limited infrastructure for PPT research,
730 development and investigative testing beyond respirator issues. The PPT
731 Program is planning to expand its capability in protective clothing
732 research, development and investigative testing through training,
733 additional personnel, and cooperative efforts with third party certification
734 authorities and laboratories.
- 735 2.3.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR
736 Part 84
- 737 2.3.1.1.3 Collaboration between Users/Other Agencies and the PPT Program.
- 738 2.3.1.1.3.1 The comfort of a respirator may impact the user’s ability to tolerate
739 long periods of use as would occur in the healthcare environment
740 during a pandemic influenza. The PPT Program has served in a
741 consultant role to the Veterans Health Administration (VHA), which
742 is addressing the issue of nurses’ tolerability for respirators (i.e.,
743 filtering facepiece respirators, powered air-purifying respirators,
744 half-facepiece elastomeric respirators) in a recently-completed study
745 at the Gainesville, FL, VHA hospital Intensive Care Unit.
746 Preliminary data analysis indicates that there are two general groups
747 of nurse users of respirators and that both have different tolerance
748 capacities for long-term wear. This data is of potential import in
749 situations, such as a pandemic influenza, where lengthy work shifts
750 (e.g., >12 hours) can be anticipated.
- 751 2.3.1.1.3.2 The PPT Program is undertaking a 2008 study (The Impact of
752 Respirator Use on Carbon Dioxide and Oxygen Saturation, Project
753 ID 921ZBFS) to determine carbon dioxide and oxygen levels in
754 healthcare workers who wear respirators (i.e., N95FFR with and
755 without exhalation valves, and with and without surgical mask
756 overlay, elastomeric half-facepiece respirators) for prolonged periods
757 as would occur in a pandemic influenza. If elevated CO2 levels or
758 depressed O2 levels are measured that would lead to symptoms,
759 mitigation strategies can be developed.
- 760 2.3.1.1.3.3 Possible project on doffing garments.
- 761 2.3.2 Develop standards for other than respirators.
- 762 2.3.2.1 Identify approaches to address gaps.

- 763 2.3.2.1.1 An assessment of current standards needs to be conducted to categorize
764 existing PPE as it relates to current standards. NPPTL currently certifies
765 performance of respirators, other PPE performance is assessed by third
766 party certification authorities in accordance with consensus standards' test
767 methods. The PPT Program has limited infrastructure for PPT research,
768 development and investigative testing beyond respirator issues. The PPT
769 Program is planning to expand its capability in protective clothing
770 research, development and investigative testing through training,
771 additional personnel, and cooperative efforts with third party certification
772 authorities and laboratories.
- 773 2.3.2.1.2 Other PPE performance is assessed by third party certification authorities
774 in accordance with consensus standards' test methods.
- 775 2.3.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.
- 776 2.4 Durability – Adequate wear life, Strength—(tear, tensile, burst), Abrasion resistance,
777 Corrosion resistance.
- 778 2.4.1 Develop standards for respiratory PPE.
- 779 2.4.1.1 Identify approaches to address gaps.
- 780 2.4.1.1.1 Existing and ongoing revisions of ANSI, ISO and other applicable
781 respiratory protection consensus standards are being assessed for
782 alignment and potential adoption by the PPT Program.
- 783 2.4.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR
784 Part 84. [Reference [S](#)]
- 785 2.4.1.1.3 Collaboration with ISEA and PPT Program.
- 786 2.4.2 Develop standards for other than respirators. Long term research.
- 787 2.4.2.1 Identify approaches to address gaps.
- 788 2.4.2.1.1 An assessment of current standards needs to be conducted to categorize
789 existing PPE as it relates to current standards. NPPTL currently certifies
790 performance of respirators, other PPE performance is assessed by third
791 party certification authorities in accordance with consensus standards' test
792 methods. The PPT Program has limited infrastructure for PPT research,
793 development and investigative testing beyond respirator issues. The PPT
794 Program is planning to expand its capability in protective clothing
795 research, development and investigative testing through training,
796 additional personnel, and cooperative efforts with third party certification
797 authorities and laboratories.
- 798 2.4.2.1.2 Other PPE performance is assessed in accordance with consensus
799 standards' test methods
- 800 2.4.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.
- 801 2.5 Maintenance and Reuse – Easy to decontaminate and discard disposable elements, Easy to
802 clean and replace parts in reusable PPE.
- 803 2.5.1 Develop standards for respiratory PPE.
- 804 2.5.1.1 Identify approaches to address gaps.
- 805 2.5.1.1.1 Existing and ongoing revisions of ANSI, ISO and other applicable
806 respiratory protection consensus standards are being assessed for
807 alignment and potential adoption by the PPT Program.

- 808 2.5.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR
809 Part 84. [Reference [S](#)]
- 810 2.5.1.1.3 Collaboration with Users/Other Agencies and the PPT Program.
- 811 2.5.2 Develop standards for other than respirators.
- 812 2.5.2.1 Identify approaches to address gaps.
- 813 2.5.2.1.1 An assessment of current standards needs to be conducted to categorize
814 existing PPE as it relates to current standards. NPPTL currently certifies
815 performance of respirators, other PPE performance is assessed by third
816 party certification authorities in accordance with consensus standards' test
817 methods. The PPT Program has limited infrastructure for PPT research,
818 development and investigative testing beyond respirator issues. The PPT
819 Program is planning to expand its capability in protective clothing
820 research, development and investigative testing through training,
821 additional personnel, and cooperative efforts with third party certification
822 authorities and laboratories.
- 823 2.5.2.1.2 Other PPE performance is assessed by third party certification authorities
824 in accordance with consensus standards' test methods
- 825 2.5.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.
- 826 2.6 Aesthetics – Variety of styles and colors, Customizable.
- 827 2.6.1 The PPT Program and Standards Development Organizations (SDO) to develop
828 performance –based standards to allow maximum customization and design to meet
829 customer aesthetic desires without adversely impacting performance.
- 830 2.6.1.1 An assessment of current standards needs to be conducted to categorize existing
831 PPE as it relates to current standards. NPPTL currently certifies performance of
832 respirators, other PPE performance is assessed by third party certification
833 authorities in accordance with consensus standards' test methods.
- 834 2.6.1.2 PPT Program will conduct a workshop in 2008 to assess the current state of
835 technology. A commerce business daily presolicitation for a contractor to
836 coordinate and conduct the workshop was published on Nov 8, 2007. [Reference
837 [D](#)]
- 838 2.6.2 ** Apprise PPE manufacturers of the ability to use new technologies, and identified
839 available technologies, to address users' aesthetic desires.
- 840 2.7 Cost - Product cost, Total life-cycle cost, Minimal environmental impact
- 841 2.7.1 PPT Program will conduct a workshop in 2008 to assess the current state of
842 technology. A commerce business daily presolicitation for a contractor to
843 coordinate and conduct the workshop was published on Nov 8, 2007. [Reference
844 [D](#)]
- 845 2.7.2 ** Apprise PPE manufacturers of capabilities to increase cost effectiveness of
846 PPE.

ID		Task Name	Recommendation #2 Gantt Chart																																															
			2007		2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018					
			Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4		
1		2.0 Define evidence based performance requirements	[Gantt bar spanning 2007-2018]																																															
2		2.1 Functionality	[Gantt bar spanning 2007-2018]																																															
3		2.1.1.3.1 Public use respirator for flu	[Gantt bar spanning 2007-2018]																																															
4		2.2 Usability	[Gantt bar spanning 2007-2018]																																															
5		2.2.1.3.1 NIOSH anthropometric program	[Gantt bar spanning 2007-2018]																																															
6		2.3 Comfort & wearability	[Gantt bar spanning 2007-2018]																																															
7		2.3.1.3.1 Effect of respirator light & moderate work rates	[Gantt bar spanning 2007-2018]																																															
8		2.4 Durability	[Gantt bar spanning 2007-2018]																																															
9		2.5 Maintenance & reuse	[Gantt bar spanning 2007-2018]																																															
10		2.1.1-2.5.1 Develop respiratory standards	[Gantt bar spanning 2007-2018]																																															
11		2.1.1-2.5.1.1 Identify approaches to addr. Gaps	[Gantt bar spanning 2007-2018]																																															
12		2.1.1-2.5.1.1.1 Conduct assess. of current standards	[Gantt bar spanning 2007-2018]																																															
13		2.1.1-2.5.1.1.2 NIOSH certifies respirators	[Gantt bar spanning 2007-2018]																																															
14		2.1.1-2.5.1.1.3 Collaborate w/ ISEA & other PPT Programs	[Gantt bar spanning 2007-2018]																																															
15		2.1.2-2.5.2 Develop standards for other PPE	[Gantt bar spanning 2007-2018]																																															
16		2.1.2-2.5.2.1 Identify approaches to addr. Gaps	[Gantt bar spanning 2007-2018]																																															
17		2.1.2-2.5.2.1 Other PPE w/ consensus test methods	[Gantt bar spanning 2007-2018]																																															
18		2.1.2-2.5.2.1.1 Collaborate w/ ISEA, ASTM, ISO, ANSI	[Gantt bar spanning 2007-2018]																																															
19		2.6 Aesthetics	[Gantt bar spanning 2007-2018]																																															
20		2.7 Cost	[Gantt bar spanning 2007-2018]																																															

DRAFT

852 IOM Recommendation # 3: Adopt a Systems Approach to the Design and Development of PPE
853 (Chap 3, p 106)

854

855 NIOSH should promote a systems approach to the design, development, testing, and certification
856 of PPE using evidence-based performance requirements or prescriptive standards and fostering
857 closer collaboration between the users, manufacturers, and research and regulatory agencies.

858

859 ***PPT Program Plan in response to IOM Recommendation # 3***

860 3.1 Standardize on a system safety plan with six phases (Concept, Definition,
861 Development, Production, Deployment and Disposition). The concept phase is the
862 initial period in which background and future technologies are developed to give a
863 basis for the proposed system hazard analysis. The definition phase allows for
864 verification of the initial design and engineering of the PPE. The development phase
865 provides system input for environmental impact, PPE engineering, integration support
866 and use studies. The production phase is where the PPE is manufactured and quality
867 control inspection and testing is achieved. The deployment phase is where the PPE
868 becomes available to the users and training and auditing is done. The disposition
869 phase is where the PPE is retired and disposed of correctly.

870 3.1.1 Evidence based performance requirements from recommendation number two
871 should be used as inputs into these activities.

872 3.1.2 Outputs from 4.3 are to be used as inputs into these activities.

873 3.1.3 Examine appropriate regulations for gaps where systems-approach requirements
874 could be added to existing standards.

875 3.1.4 The program in place for CBRN/NFPA SCBA could be considered as a model
876 for “lessons learned”.

877 3.1.5 Some testing required to developing a healthcare system is currently underway
878 and will inform future options, i.e. N95 v P100, full facepiece respirator use,
879 adhesive seal respirators, fit test evaluations [Reference [E](#)], and cough study
880 [Reference [B](#)].

881 3.2 What immediate systemic or strategic measures can be taken to facilitate closer
882 collaboration between healthcare workers (end users), PPE manufacturers, and certification
883 or regulatory agencies on the design and development of PPE for healthcare?

884 3.2.1 Improved outreach approaches directed to healthcare worker PPE users, including
885 professional societies and labor representatives, to participate and provide input in
886 public meetings and postings of research proposals, research objectives, approval
887 performance criteria, etc. Near term research.

888 3.2.1.1 Determine strategies to simulate and enhance healthcare worker
889 participation in standards development committees, public meetings and research
890 activities.

891 3.2.1.1.1 ** Funding sources need identified.

892 3.2.1.2 Currently, Occupational Medicine residency programs graduate < 100
893 physicians per year in the U.S. and many of these individuals enter
894 academia. Many medically-related Occupational Medicine tasks (e.g.,
895 respirator fit testing, audiology testing and review, baseline pulmonary
896 function interpretations, etc.) are overseen by Internal Medicine and
897 Family Medicine practitioners who may have limited training in these


898 areas. During a pandemic influenza, demands on these practitioners
899 regarding such issues as respirator fit testing may take on additional
900 importance. The PPT Program has developed a one-day Occupational
901 Medicine rotation at NPPTL, for Internal Medicine and Family Medicine
902 resident physicians that offer instruction in such areas as audiology,
903 respirator fit testing, and shadowing of an Occupational Medicine
904 physician in the NPPTL Occupational Medicine clinic. This outreach
905 endeavor will serve to increase the medical practitioner's Occupational
906 Medicine skills and also make him/her aware of NPPTL services that may
907 be of use to the practitioner.

DRAFT

2/5/2008

IOM Recommendation #3

PPT Program Response



Recommendation #3 Gantt Chart																																															
ID	Task Name	2007		2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018			
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4								
1	3.0 Adopt system approach to design & dev. PPE	[Blue bar spanning from Q1 2008 to Q4 2018]																																													
2	3.1.1 Standardize on system safety plan for PPE	[Blue bar spanning from Q1 2008 to Q4 2015]																																													
3	3.1.1.1 Examine evidence based perf (recommendation #2)	[Blue bar spanning from Q1 2008 to Q4 2015]																																													
4	3.1.1.2 Examine appropriate regs for adherence	[Blue bar spanning from Q1 2008 to Q4 2013]																																													
5	3.1.1.3 Examine models in place CBRN/NFPA SCBA	[Blue bar spanning from Q1 2008 to Q4 2009]																																													
6	3.2.0 Facilitate collaboration with HCWs	[Blue bar spanning from Q1 2008 to Q4 2011]																																													
7	3.2.1 Improve outreach	[Blue bar spanning from Q1 2008 to Q4 2011]																																													
8	3.2.1.1 PPT Program 1 day rotation Occ. Medicine	[Blue bar spanning from Q1 2008 to Q4 2009]																																													

DRAFT

913 IOM Recommendation # 4: Increase Research on the Design and Engineering of the Next
914 Generation of PPE (Chap 3, p 106-107)

915

916 NIOSH, the Department of Homeland Security, the Department of Defense, manufacturers, and
917 other relevant organizations and agencies should fund research directed at the design and
918 development of the next generation of respirators, gowns, gloves, and eye protection for
919 healthcare workers that would enhance their safety and comfort.

920

921 ***PPT Program Plan in response to IOM Recommendation # 4***

922 4.1 Utilizing innovations in materials such as shape memory polymers (e.g., to obviate fit
923 testing and enhance fit of respirators and comfort of gowns) and finishing treatments (e.g.,
924 safe antimicrobial or biocidal finishes)

925 4.1.1 What technologies can improve fit to circumvent the need for fit testing?

926 4.1.1.1 NIOSH conducted workshops with RAND Jan 2004 to identify future PPE
927 needs.

928 4.1.1.2 Nov 30 - Dec1 2004 PPT Program conducted workshop to assess current state
929 of knowledge of infectivity of bioaerosol: Reference [C](#).

930 4.1.1.3 PPT Program will conduct workshop in 2008 to assess the current state of
931 technology. A commerce business daily presolicitation was published on Nov 8,
932 2007. Reference [D](#).

933 4.1.2 What innovative designs can improve wearability issues regarding PPE?

934 4.1.2.1 NIOSH conducted workshops with RAND Jan 2004 to identify future PPE
935 needs.

936 4.1.2.2 Nov 30 - Dec1 2004 PPT Program conducted workshop to assess current state
937 of knowledge of infectivity of bioaerosol: Reference [C](#).

938 4.1.2.3 PPT Program will conduct workshop in 2008 to assess the current state of
939 technology. A commerce business daily presolicitation was published on Nov
940 8, 2007. Reference [D](#).

941 4.2 Developing more effective and consistent faceseals for respirators, including examination
942 of the effect of wear and repeated donning and doffing on the quality of the faceseal of
943 filtering facepiece respirators, and research on the effect of respirator filter efficiency on
944 faceseal leakage and degree of protection

945 4.2.1 What are the differences in protection of N95 versus N100 or other respirators if
946 exposed to human and avian influenza aerosols?

947 4.2.1.1 PPT Program is conducting research on relative performance of N95 and P100
948 Filtering Facepiece Respirators (FFRs) in laboratory protection level studies.
949 The draft protocol incorporates human subject testing planned using NPPTL
950 generated aerosol (corn oil and sodium chloride) and ambient aerosol
951 (PortaCount Plus) fit test facilities. Test results would be applicable to virus
952 particles (whether aerosol or droplet transmission). Reference [E](#).

953 4.2.2 Could a nondisposable respirator be designed that could be easily decontaminated and
954 cost-effective?

955 4.2.2.1 Ease of acceptable decontamination procedures are dependent on virulence of
956 virus and effectiveness of decontamination methods.

957 4.2.2.2 Possible project to study antimicrobial respirator technology.


- 958 4.2.3 Study of efficacy of user seal checks on filtering face-piece: Reference [E](#). The user
959 seal check is required with every donning of the respirator to verify that an adequate
960 fit has been achieved. However, the value of the user seal check has not been
961 adequately demonstrated in the literature.
- 962 4.2.4 Develop a request for proposal (RFP) to solicit development of innovative products
963 through the NIOSH/OEP.
- 964 4.2.4.1 ** Funding sources need to be identified.
- 965 4.3 Providing a seamless interface between PPE (e.g., eye protection and respirators)
- 966 4.3.1 Some of the lessons learned in the current project. Next Generation Structural Fire
967 Fighting PPE Ensemble may be applicable to healthcare PPE, even though it doesn't
968 apply to pandemic flu. Reference [F](#).
- 969 4.3.2 Outputs of activities should be provided as input to recommendation number three
970 3.1.
- 971 4.4 Designing respirator facepieces to integrate medical devices such as a stethoscope and to
972 improve communication between the user and others.
- 973 4.4.1 ** Apprise PPE manufacturers.
- 974 4.5 Establishing a new set of performance requirements for PAPRs and for reusable filtering
975 facepiece respirators that meet the needs of healthcare workers
- 976 4.5.1 Current PAPRs are designed to provide extremely high flow rates to protect the
977 worker in an industrial setting. While appropriate to protect from significant dust
978 exposures, they present serious design impediments for the healthcare worker. What
979 are the flow rates and maximum noise levels that would be required for NIOSH to
980 certify a PAPR that would provide adequate protection for healthcare workers? What
981 is the risk to patients from healthcare workers wearing PAPRs (from unfiltered
982 exhaled air), and what design modifications would be needed to eliminate such risk as
983 well as facilitate interactions with patients?
- 984 4.5.1.1 PPT Program has developed concept for new PAPR certification provisions that
985 would allow approval of 3 classes of PAPR with flow rates applicable to low,
986 medium and high work rates. [Reference [G](#)] The concept also addresses
987 incorporation of sensors into PPE to detect breaches and notify users of end of
988 service life and other protection information.
- 989 4.5.1.2 Respirators utilized in healthcare settings were not designed for that particular
990 venue. Therefore, there are features of respirators that do not necessarily lend
991 themselves well to the healthcare environment. The PPT Program, in
992 conjunction with the VHA and academia initiated Project BREATHE (Better
993 Respiratory Equipment And Technology for Healthcare Employees). Currently
994 in its developmental stages, this endeavor initially will bring together a working
995 group consisting of healthcare workers and respirator experts from academia
996 and government that will address respirator characteristics germane to
997 healthcare workers (e.g., speech intelligibility, visibility, hearing, etc.) with the
998 goal of identifying features (e.g., clear silicone components, speech diaphragms,
999 etc.) that would enhance respirator performance in the healthcare setting. The
1000 second stage of this project would consist of bringing these recommendations to
1001 respirator manufacturers with the intent of developing a respirator that is
1002 designed specifically with the healthcare worker in mind. Improved respirators


- 1003 are likely to be better tolerated during periods of prolonged use, such as
1004 influenza pandemics.
- 1005 4.6 Incorporating sensors into PPE to detect breaches and notify users of end of service life and
1006 other protection information. Sensors for face seal leakage is the key issue in this
1007 recommendation. If the PPE was not donned properly or no longer fitting, can this be
1008 detected and the user alerted?
- 1009 4.6.1 Can the protection levels of the PPE worn by healthcare workers (e.g., N95
1010 respirators) be continuously monitored during use to provide an alert to change the
1011 PPE when it is no longer effective?
- 1012 4.6.1.1 PPT Program will conduct workshop in 2008 to assess the current state of
1013 technology. A commerce business daily presolicitation was published on Nov
1014 8, 2007. Reference [D](#).
- 1015 4.6.1.2 PPT Program – New Sensor Technology Development for ESLI: Reference [H](#).
1016 Even though this project doesn't apply directly to pandemic flu it may be
1017 possible to use some of the lessons learned in this project and apply it to
1018 healthcare PPE (ie like working with manufacturers to develop sensor
1019 technology).
- 1020 4.6.2 Develop other-than-respiratory PPE with technology to alert the user when
1021 effectiveness may be compromised.
- 1022 4.6.2.1 Add colorimetric write-up.
- 1023 4.6.2.2 Add innovative indicator write-up for chemical protective clothing (CPC).
1024

2/5/2008

IOM Recommendation #4

PPT Program Response





DRAFT

1031 IOM Recommendation # 5: Establish Measures to Assess and Compare the Effectiveness of PPE
1032 (Chap 3, p 107)

1033
1034 NIOSH, through NPPTL, should develop and promote a validated set of measures for comparing
1035 the effectiveness of PPE products. The goal is a set of measures that would allow users to
1036 compare and select appropriate PPE commensurate with the assessed risk and desired level of
1037 protection. Particular attention should be paid to disseminating information to healthcare workers
1038 on PPE effectiveness relevant to influenza.

1039

1040 ***PPT Program Plan in response to IOM Recommendation # 5***

1041 5.1 Expedited efforts to finalize a standardized method for measuring the total inward leakage
1042 of respirators as part of the NIOSH respirator approval protocols

1043 5.1.1 The NPPTL Total Inward Leakage (TIL) Program will establish TIL performance
1044 requirements and laboratory test capability for testing of PPE including all classes of
1045 respirators and protective garments. The initial TIL project will address half-mask
1046 respirator requirements and testing. Other classes of respirators will be incorporated
1047 into the program following completion of the half-mask project. Respirator TIL
1048 testing is intended to quantify the ability of respirators to fit a range of facial
1049 dimensions, representative of the US workforce. Total inward leakage testing
1050 performed under laboratory conditions represents a criterion for performance that will
1051 influence PPE design. PPT Program – TIL initiative: Reference [I](#).

1052 5.2 Develop and promote filter efficiency measures

1053 5.2.1 For what period of time does PPE remain contaminated with infectious influenza
1054 viruses, and what improvements can be made in doffing and decontamination
1055 procedures given that information?

1056 5.2.1.1 Assess the viability of influenza virus on filter media: Reference [A](#).

1057 5.2.1.2 Explore efficacy in collaboration with CDC, FDA and EPA: Reference [A](#).

1058 5.2.1.3 Collaborate with PPT manufacturers: Reference [A](#).

1059 5.3 Develop and promote measures for comparing the effectiveness of respirators, gowns,
1060 gloves, eye protection, and other types of PPE based on evidence-based performance
1061 requirements.

1062 5.3.1 NIOSH has a well established anthropometrics research program in both facial and
1063 whole body anthropometrics. The current initiatives will be examined to determine
1064 how recommendations can be addressed.

1065 5.3.1.1 The PPT Program Facial Anthropometrics Research Roadmap was created in
1066 September 2007 and posted on the web for comment. The comment period will
1067 be open until 22 February 2008. The plan can be found here. Reference [R](#).

1068 5.3.1.2 DSR input for whole body anthropometrics ongoing activities. References [T](#).

1069 5.3.2 How does the penetration risk of N95 respirators made of different materials and
1070 designs change with high inhalation rates?

1071 5.3.2.1 PPT Program will conduct workshop in 2008 to assess the current state of
1072 technology. A commerce business daily presolicitation was published on Nov
1073 8, 2007. Reference [D](#).

1074 5.3.3 What are the appropriate PPE decontamination strategies that would not compromise
1075 the integrity of the PPE while being easy and cost-effective to implement in a
1076 healthcare setting?

- 1077 5.3.3.1 PPT Program is currently investigating effects of decontamination procedures
1078 on respirator performance: Reference [A](#). PPT Program to collaborate with CDC
1079 Division of Hospital Infections re: biology of virus and best possible
1080 decontamination procedures.
- 1081 5.3.4 Do specific procedures (e.g., nebulization, endotracheal intubation, bronchoscopy,
1082 cleaning of patients' rooms) place healthcare workers at higher levels of risk of
1083 influenza infection? To what extent do various types of PPE offer protection during
1084 these procedures and processes?
- 1085 5.3.4.1 ** (same as 1.3.5 under recommendation #1)
- 1086 5.3.5 How does the level of protection afforded by N95 change with and without fit
1087 testing? What is the impact of masking influenza patients on transmission risk? If
1088 effective, how long before the respirator needs to be changed?
- 1089 5.3.5.1 Describe the FDA Community use respirator and the science behind the
1090 decisions (for question 1)
- 1091 5.3.5.2 Seasonal influenza studies should be conducted in collaboration with other
1092 NIOSH programs, CDC and NIAID.
- 1093 5.3.6 What are the best practices for PPE removal to minimize risk of self-inoculation?
- 1094 5.3.6.1 Assess the viability of influenza virus on filter media: Reference [A](#).
- 1095 5.3.6.2 Explore efficacy in collaboration with CDC, FDA and EPA: Reference [A](#).
- 1096 5.3.6.3 Collaborate with PPT manufacturers: Reference [A](#).
- 1097 5.3.7 What are the risks of self-inoculation when changing PPE (i.e., is the true acquisition
1098 risk the same when wearing a medical mask and changing to an N95 for high-risk
1099 procedures versus wearing an N95 throughout the shift?)
- 1100 5.3.7.1 Assess the viability of influenza virus on filter media: Reference [A](#).
- 1101 5.3.7.2 Explore efficacy in collaboration with CDC, FDA and EPA: Reference [A](#).
- 1102 5.3.7.3 Collaborate with PPT manufacturers: Reference [A](#).
- 1103 5.3.8 What protective roles do gloves, gowns, and face shields or other eye protection play
1104 in preventing influenza transmission?
- 1105 5.3.8.1 ** (same as 1.3.5 under recommendation #1)
- 1106 5.3.9 What protection would medical masks provide to the wearer during an influenza
1107 pandemic?
- 1108 5.3.9.1 ** (same as 1.3.5 under recommendation #1)
- 1109 5.3.9.2 Currently, the performance effectiveness of medical masks is assessed in
1110 accordance with consensus standards' test methods.
- 1111 5.3.10 On going PPT Program research activities
- 1112 5.3.10.1 Development and validation of PPE preconditioning methods: Reference [J](#).
- 1113 5.3.10.2 Reusability of filtering facepiece respirators: Reference [A](#).
- 1114 The availability of FFR during a pandemic influenza is a subject of concern.
1115 Respirator manufacturers have warned that they may not be able to keep up with
1116 the anticipated demand. This has placed more emphasis upon the idea of
1117 decontaminating FFR for reuse. The PPT Program initiated a study in 2007
1118 (Reusability of Filtering Facepiece Respirators Exposed to Influenza Virus
1119 Simulant) to address the reusability of filtering facepiece respirators following
1120 various types of decontamination (e.g., heat, soap & water, chemicals,
1121 ultraviolet light, gas sterilization, microwaving). The data from this study have
1122 been analyzed and a manuscript prepared for journal submission. The data

1123 categorize the various decontamination agents with respect to their effects on
1124 filtration performance of the respirator.


1125 5.3.10.3 Improve criteria for emergency medical protective clothing (EMS): Reference
1126 [K](#). The PPT Program has undertaken a project to address the issue of protective
1127 clothing for Emergency Medical Services personnel who respond to patients
1128 with infectious diseases (approximately 1/29 of EMS calls), such as influenza,
1129 by contracting a study (Improved Criteria for Emergency Medical Protective
1130 Clothing – Project Plan Purchase Order No. 214-2006-M-15870) The objective
1131 of this project is to support the improvement of criteria for specific types of
1132 emergency medical personal protective equipment that are used by first
1133 responders. This objective specifically is defined to cover single use garments,
1134 cleaning gloves, footwear covers, and eye/face protection devices. A secondary
1135 objective of the project is to support the NFPA Technical Committee on
1136 Emergency Medical Services Protective Clothing and Equipment in its
1137 standards development process for modification of NFPA 1999 during its 2008
1138 revision process. The project is intended to provide technical support for the
1139 committee to justify changes to the standard, particularly as related to changes
1140 in performance criteria.


1141 5.3.10.4 Metabolic evaluation of N95 respirator use with surgical masks: Reference [J](#).
1142 The IOM and the CDC have suggested that, in the face of reduced availability
1143 of filtering facepiece respirators, surgical masks placed over these respirators as
1144 a barrier might prolong their useful life. Although this recommendation has
1145 some plausibility, it has not undergone scientific scrutiny. The PPT Program
1146 initiated a study in 2006 (Metabolic Evaluation of N95 Respirator Use with
1147 Surgical Masks), utilizing an Automated Breathing and Metabolic Simulator to
1148 evaluate the concurrent use of N95FFR with surgical mask overlay. Within-
1149 respirator carbon dioxide levels, oxygen levels, and breathing resistance are
1150 being monitored to determine the effect(s) of the surgical mask on these
1151 parameters. Knowledge of these data can help predict physiological effects on
1152 wearers during prolonged periods of use, such as during a pandemic influenza.
1153 This recently-completed study (2007) by personnel from the PPT Program
1154 demonstrated that placement of a surgical mask over various models of N95FFR
1155 results in elevated breathing resistance (increases of $\pm 8\%$ - 10% during
1156 inhalation and exhalation). This mannequin-based study suggests that use of a
1157 surgical mask as a barrier over a FFR will not result in breathing resistance that
1158 will have a pronounced effect upon the wearer. The data from this study will
1159 eventually be compared with that from the current study utilizing the Automated
1160 Breathing and Metabolic Simulator for correlative analysis.

2/5/2008

IOM Recommendation #5

PPT Program Response





DRAFT

1167 IOM Recommendation # 6: Emphasize Appropriate PPE Use in Patient Care and in Healthcare
1168 Management, Accreditation, and Training (Chap 4, p 140)

1169

1170 Appropriate PPE use and healthcare worker safety should be a priority for healthcare
1171 organizations and healthcare workers, and in accreditation, regulatory policy, and training.

1172

1173 ***PPT Program Plan in response to IOM Recommendation # 6***

1174 6.1 Healthcare employers should strengthen their organization's commitment to a culture of
1175 safety by providing leadership in worker safety; instituting comprehensive, state-of-the-art
1176 training and education programs; facilitating easy access to PPE; giving feedback to
1177 supervisors and employees on PPE adherence; and enforcing disciplinary actions for
1178 noncompliance. Near term research.

1179 6.1.1 A commitment by healthcare employers to promoting, training, and enforcing PPE
1180 compliance could increase adherence to PPE protocols and foster the expectation and
1181 norm for appropriate PPE use.

1182 6.1.1.1 Improved outreach approaches directed to healthcare users and facilities,
1183 including professional societies and labor representatives to disseminate PPT
1184 Program recommendations and guidance. NPPTL has participated in the
1185 Association of PeriOperative Healthcare Nurses conference for the last two
1186 years and will be participating with an exhibit and materials in March 2008. We
1187 also participated in the EMS Update in Champion PA in 2007 and are scheduled
1188 to return in 2008. Also exhibited at the Association of Occupational
1189 HealthProfessionals in 2007 and plan to return in 2008.

1190 6.1.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1191 guidance in healthcare in collaboration with NIOSH, CDC, and others

1192 6.2 Healthcare workers should take responsibility for their safety by working to enhance the
1193 culture of safety in the workplace and by adhering to PPE protocols.

1194 6.2.1 A commitment by healthcare employers to promoting, training, and enforcing PPE
1195 compliance could increase adherence to PPE protocols and foster the expectation and
1196 norm for appropriate PPE use. Near term research.

1197 6.2.1.1 Improved outreach approaches directed to healthcare users and facilities,
1198 including professional societies and labor representatives to disseminate PPT
1199 Program recommendations and guidance.


1200 6.2.1.1.1 PPT Program is currently involved in undertaking a project with members
1201 of the Association of Occupational Health Practitioners in Medicine
1202 (AOHP) regarding manpower issues in annual respirator fit testing. Many
1203 AOHP members (most of whom are Registered Nurses who function
1204 within Employee Health clinics at healthcare institutions) contend that
1205 they do not have the necessary manpower to carry out OSHA-mandated
1206 annual fit testing for employees. This important issue in protecting
1207 healthcare workers takes on additional importance in the face of the
1208 increased infectious exposure that would occur during an influenza
1209 pandemic. PPT Program and AOHP members are developing a pilot
1210 program that will utilize a survey instrument (questionnaire) to determine
1211 the numbers of fit tests required per year and the available staff to carry
1212 out such testing in several local (Pittsburgh) hospitals. Data from the pilot

- 1213 program will be utilized to promote a larger study which will, in turn,
1214 identify manpower needs for annual fit testing in the healthcare
1215 community and how to more adequately utilize that manpower.
- 1216 6.2.1.1.2 PPT Program has initiated contact with officials at the University of
1217 Pittsburgh's School of Public Health to look at areas of mutual interest
1218 with the eventuality of possibly engaging in research together.
- 1219 6.2.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1220 guidance in healthcare in collaboration with NIOSH, CDC, and others
- 1221 6.2.2 How can the safety culture of healthcare facilities be improved? What approaches
1222 best facilitate a healthcare organizational culture that promotes safety? Long term
1223 research.
- 1224 6.2.2.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to
1225 establish approaches directed to healthcare users and facilities, including
1226 professional societies and labor representatives to disseminate and enforce PPT
1227 protocols, guidance and compliance issues.
- 1228 6.2.2.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1229 guidance in healthcare in collaboration with NIOSH, CDC, and others
- 1230 6.3 Healthcare accrediting organizations (including the Joint Commission and state health
1231 departments) should set, implement, and enforce work standards in hospitals and other
1232 healthcare facilities to ensure that proper use of PPE is a priority and a sentinel event
1233 subject to controls at the administrative, supervisory, and individual levels.
- 1234 6.3.1 Efforts by the Joint Commission and state health departments to emphasize PPE
1235 compliance in accreditation and other assessments could focus attention on PPE
1236 issues and enhance adherence to PPE protocols.
- 1237 6.3.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to
1238 establish approaches directed to healthcare users and facilities, including
1239 professional societies and labor representatives to disseminate and enforce PPT
1240 protocols, guidance and compliance issues.
- 1241 6.4 Healthcare accrediting and credentialing organizations should ensure that PPE training is
1242 part of the accreditation and testing curricula of health professional schools of nursing,
1243 medicine, and allied health and that PPE concepts and practice are included on certification
1244 examinations and as continuing education training requirements.
- 1245 6.4.1 Efforts by the Joint Commission and state health departments to emphasize PPE
1246 compliance in accreditation and other assessments could focus attention on PPE
1247 issues and enhance adherence to PPE protocols.
- 1248 6.4.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to
1249 establish approaches directed to healthcare users and facilities, including
1250 professional societies and labor representatives to disseminate and enforce PPT
1251 protocols, guidance and compliance issues.
- 1252 6.4.2 PPT Program pilot program for training on PPE use. The PPT Program has instituted
1253 an Occupational Medicine rotation at NPPTL for Internal Medicine and Family
1254 Medicine resident physicians to acclimate them to issues that are germane to their
1255 involvement in Occupation Medicine tasks.

2/5/2008

IOM Recommendation #6

PPT Program Response



		Recommendation #6 Gantt Chart																																															
ID	Task Name	2007		2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018					
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4						
1	6.0 Emphasize appropriate PPE use	[Gantt bar from Q3 2007 to Q4 2018]																																															
2	6.1 HCF strengthen commitment to safety	[Gantt bar from Q3 2007 to Q4 2018]																																															
3	6.1.1 HCF commitment to training & compliance	[Gantt bar from Q3 2007 to Q4 2018]																																															
4	6.1.1.1 Improve outreach	[Gantt bar from Q3 2007 to Q4 2018]																																															
5	6.1.1.2 Cont. eval. of effectiveness PPT Program	[Gantt bar from Q3 2007 to Q4 2018]																																															
6	6.2 Promote HCW to take responsibility for self	[Gantt bar from Q3 2007 to Q4 2018]																																															
7	6.2.1.1.1 Fit testing manpower issues	[Gantt bar from Q3 2007 to Q4 2018]																																															
8	6.2.1.1.2 Collaboration Pitt Public Health	[Gantt bar from Q3 2007 to Q4 2018]																																															
9	6.2.2 Study change in safety culture	[Gantt bar from Q3 2007 to Q4 2018]																																															
10	6.2.2.1 Improve Collaboration amongst HCO	[Gantt bar from Q3 2007 to Q4 2018]																																															
11	6.3 Healthcare accrediting org. take enforcement lead	[Gantt bar from Q3 2007 to Q4 2018]																																															
12	6.3.1 Coordination of efforts for compliance in accreditation	[Gantt bar from Q3 2007 to Q4 2018]																																															
13	6.4 Healthcare accrediting org. take training lead	[Gantt bar from Q3 2007 to Q4 2018]																																															
14	6.4.2 Pilot study for PPE use training	[Gantt bar from Q3 2007 to Q4 2018]																																															

DRAFT

1260 IOM Recommendation # 7: Identify and Disseminate Best Practices for Improving PPE
1261 Compliance and Use (Chap 4, p 140-141)

1262
1263 CDC and the Agency for Healthcare Research and Quality (AHRQ) should support and evaluate
1264 demonstration projects on improving PPE compliance and use. This effort would identify and
1265 disseminate relevant best practices that are being used by hospitals and other healthcare facilities.
1266

1267 ***PPT Program Plan in response to IOM Recommendation # 7***


- 1268 7.1 Demonstrate, implement, evaluate, and improve the integration of worker safety into the
1269 protocols and practice of the organization.
- 1270 7.1.1 ** Near and long term opportunities are available for early identification influenza
1271 patients.
- 1272 7.1.1.1 ** These needs may be achievable under other projects or grants.
- 1273 7.2 Develop, implement, and evaluate evidence-based training programs on risk assessment
1274 and the use of PPE, including addressing practical realities of wearing PPE, donning and
1275 doffing, decontamination, and waste disposal
- 1276 7.2.1 What are the best ways to train healthcare workers on appropriate use of personal
1277 protective equipment? What is the feasibility of fit testing and “just-in-time” training?
- 1278 7.2.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to
1279 establish approaches directed to healthcare users and facilities, including
1280 professional societies and labor representatives to disseminate and enforce PPT
1281 protocols, guidance and compliance issues.
- 1282 7.2.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1283 guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 1284 7.2.1.2.1 PPT Program personnel recently completed a study (Mannequin-based
1285 Study of N95 Filtering Facepiece Respirators Worn Concurrently With a
1286 Loose-fitting, Powered Air-purifying Respirator: Effect on Protection
1287 Factors) that addressed the issue of wearing an N95FFR underneath a
1288 PAPR as is frequently done by healthcare workers performing potentially
1289 aerosol-generating procedures (e.g., suctioning, intubations, administering
1290 aerosolized medication treatments, etc.) on infectious patients, such as
1291 those with influenza. The study demonstrated that significant additional
1292 protection is afforded by this tandem respiratory combination that is
1293 especially significant in the event of PAPR failure. Publication of this data
1294 in a journal will serve to disseminate this information to the healthcare
1295 community.
- 1296 7.3 Develop, implement, and evaluate worker safety communication programs focusing on
1297 infection control, PPE, and reduction of risk and barriers during an influenza pandemic.
- 1298 7.3.1 What are the best mechanisms to communicate with and receive feedback from
1299 frontline healthcare workers in order to ensure that infection control measures are
1300 practical and feasible while still enhancing safety?
- 1301 7.3.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to
1302 establish approaches directed to healthcare users and facilities, including
1303 professional societies and labor representatives to disseminate and enforce PPT
1304 protocols, guidance and compliance issues.

- 1305 7.3.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1306 guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 1307 7.3.1.2.1 PPT Program personnel recently completed a study (Mannequin-based
1308 Study of N95 Filtering Facepiece Respirators Worn Concurrently With a
1309 Loose-fitting, Powered Air-purifying Respirator: Effect on Protection
1310 Factors) that addressed the issue of wearing an N95FFR underneath a
1311 PAPR as is frequently done by healthcare workers performing potentially
1312 aerosol-generating procedures (e.g., suctioning, intubations, administering
1313 aerosolized medication treatments, etc.) on infectious patients, such as
1314 those with influenza. The study demonstrated that significant additional
1315 protection is afforded by this tandem respiratory combination that is
1316 especially significant in the event of PAPR failure. Publication of this data
1317 in a journal will serve to disseminate this information to the healthcare
1318 community.
- 1319 7.3.2 Define and promote strategies to increase adherence to infection control.
- 1320 7.3.2.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to
1321 establish approaches directed to healthcare users and facilities, including
1322 professional societies and labor representatives to disseminate and enforce PPT
1323 protocols, guidance and compliance issues.
- 1324 7.3.2.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1325 guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 1326 7.3.2.3 PPT Program personnel recently completed a study (Mannequin-based Study of
1327 N95 Filtering Facepiece Respirators Worn Concurrently With a Loose-fitting,
1328 Powered Air-purifying Respirator: Effect on Protection Factors) that addressed
1329 the issue of wearing an N95FFR underneath a PAPR as is frequently done by
1330 healthcare workers performing potentially aerosol-generating procedures (e.g.,
1331 suctioning, intubations, administering aerosolized medication treatments, etc.)
1332 on infectious patients, such as those with influenza. The study demonstrated that
1333 significant additional protection is afforded by this tandem respiratory
1334 combination that is especially significant in the event of PAPR failure.
1335 Publication of this data in a journal will serve to disseminate this information to
1336 the healthcare community.
- 1337 7.4 Monitor, enforce, and provide feedback to supervisors and employees regarding
1338 appropriate use of PPE
- 1339 7.4.1 ** Near and long term research is needed regarding appropriate use of PPE.
- 1340 7.5 Evaluate and determine which practices are most effective regarding PPE use by healthcare
1341 workers, patients, and visitors, with a focus on respirator use.
- 1342 7.5.1 How do worker safety and patient safety interact? How can priorities be balanced
1343 where they conflict?
- 1344 7.5.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to
1345 establish approaches directed to healthcare users and facilities, including
1346 professional societies and labor representatives to disseminate and enforce PPT
1347 protocols, guidance and compliance issues.
- 1348 7.5.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1349 guidance in healthcare in collaboration with NIOSH, CDC, and others.

2/5/2008

IOM Recommendation #7

PPT Program Response



		Recommendation #7 Gantt Chart																																															
ID	Task Name	2007				2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018			
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2				
1	7.0 Identify & disseminate compliance best practices	[Gantt bar from Q3 2007 to Q4 2018]																																															
2	7.1 Improve integration of worker safety into products	[Gantt bar from Q3 2007 to Q4 2013]																																															
3	7.1.1 Apprise other agencies	[Gantt bar from Q3 2007 to Q2 2008]																																															
4	7.1.2 Study how to identify ill patients early	[Gantt bar from Q3 2007 to Q4 2012]																																															
5	7.1.2.2 Input from other NIOSH Programs	[Gantt bar from Q3 2007 to Q4 2013]																																															
6	7.2 Promote evidence based training programs	[Gantt bar from Q3 2007 to Q4 2018]																																															
7	7.2.1 Study best way to train HCW	[Gantt bar from Q3 2007 to Q4 2012]																																															
8	7.2.1.1 Improve outreach	[Gantt bar from Q3 2007 to Q4 2018]																																															
9	7.2.1.2 Cont. eval. of effectiveness PPT Prog.	[Gantt bar from Q3 2007 to Q4 2018]																																															
10	7.3 Promote worker safety programs	[Gantt bar from Q3 2007 to Q4 2013]																																															
11	7.3.1 Study feedback mechanisms	[Gantt bar from Q3 2007 to Q4 2013]																																															
12	7.3.2 Increase adherence to infection control	[Gantt bar from Q3 2007 to Q4 2013]																																															
13	7.4 Promote effective feedback programs	[Gantt bar from Q3 2007 to Q4 2018]																																															
14	7.5 Study effective respiratory practices	[Gantt bar from Q3 2007 to Q4 2013]																																															
15	7.5.1 Determine priorities and safety	[Gantt bar from Q3 2007 to Q4 2013]																																															

DRAFT

1357 IOM Recommendation # 8: Increase Research and Research Translation Efforts Relevant to PPE
1358 Compliance (Chap 4, p 141)

1359

1360 NIOSH, the National Institutes of Health (NIH), AHRQ, and other relevant agencies and
1361 organizations should support research on improving the human factors and behavioral issues
1362 related to ease and effectiveness of PPE use for extended periods and in patient care-interactive
1363 work environments.

1364

1365 ***PPT Program Plan in response to IOM Recommendation # 8***

1366 8.1 Identifying effective approaches to donning and doffing PPE, including enhancements in
1367 PPE ensemble design

1368 8.1.1 A commitment by healthcare employers to promoting, training, and enforcing PPE
1369 compliance could increase adherence to PPE protocols and foster the expectation and
1370 norm for appropriate PPE use.

1371 8.1.1.1 Improved outreach approaches directed to healthcare users and facilities,
1372 including professional societies and labor representatives to disseminate PPT
1373 Program recommendations and guidance.

1374 8.1.1.1.1 The PPT Program is directing its outreach approaches in several ways. An
1375 Occupational Medicine one-day rotation for Internal Medicine and Family
1376 Medicine residents of the West-Penn/Allegheny Health System is
1377 scheduled to commence Jan, 2008. It is hoped that this outreach program
1378 will enhance the practitioners' skills, some of which could be of
1379 significant importance in the face of an influenza pandemic (e.g.,
1380 respirator fit testing). The PPT Program is also reaching out to medical
1381 professional societies (e.g., Association of Occupational Healthcare
1382 Professionals in Medicine) to engage them in collaborative research
1383 efforts (e.g., manpower needs for annual fit testing) that can impact
1384 aspects of a pandemic influenza. The PPT Program is also engaging
1385 healthcare systems and institutions, including the VHA and the University
1386 of Pittsburgh School of Public Health (Department of Occupational and
1387 Environmental Health) in collaborative research efforts regarding PPE.
1388 Also, NPPTL has participated in the Association of PeriOperative
1389 Healthcare Nurses conference for the last two years and will be
1390 participating with an exhibit and materials in March 2008. We also
1391 participated in the EMS Update in Champion PA in 2007 and are
1392 scheduled to return in 2008. Also exhibited at the Association of
1393 Occupational Health Professionals in 2007 and plan to return in 2008.

1394 8.1.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and
1395 guidance in healthcare in collaboration with NIOSH, CDC, and others

1396 8.2 Development of standard-of-use protocols based on infection prevention and control policy
1397 with clear, simple-to-use algorithms

1398 8.2.1 What interventions prevent healthcare-acquired influenza?

1399 8.2.1.1 Seasonal influenza studies related to PPT use and effectiveness should be
1400 conducted in collaboration with other NIOSH programs, CDC and NIAID.

1401 8.3 Examination of behavioral implementation strategies for sustained use of PPE, including a
1402 focus on patient and community education as well as healthcare provider education.


- 1403 8.3.1 Is a continued focus on procedure-driven PPE feasible?
- 1404 8.3.1.1 Continuous evaluation of effectiveness of PPT Program recommendations and
- 1405 guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 1406 8.3.1.2 Improved collaboration between the PPT Program, OSHA, and JCAHO to
- 1407 establish approaches directed to healthcare users and facilities, including
- 1408 professional societies and labor representatives to disseminate and enforce PPT
- 1409 protocols, guidance and compliance issues.

DRAFT

2/5/2008

IOM Recommendation #8

PPT Program Response



Recommendation #8 Gantt Chart																																															
ID	Task Name	2007		2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018			
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4								
1	8.0 Increase research compliance efforts	[Blue bar spanning all quarters from 2007 to 2018]																																													
2	8.1 Identify effective donning & doffing	[Blue bar spanning all quarters from 2007 to 2018]																																													
3	8.1.2 Commitment by HCF to enforce compliance	[Blue bar spanning all quarters from 2007 to 2018]																																													
4	8.1.2.1 PPI Program outreach program	[Blue bar spanning all quarters from 2007 to 2018]																																													
5	8.1.2.2 Continuous eval. of PPI Program	[Blue bar spanning all quarters from 2007 to 2018]																																													
6	8.2 Development of standard of use protocols	[Blue bar spanning all quarters from 2007 to 2018]																																													
7	8.2.1 Determine which interventions are effective	[Blue bar spanning all quarters from 2007 to 2018]																																													
8	8.2.1.1 Conduct seasonal flu studies	[Blue bar spanning all quarters from 2007 to 2018]																																													
9	8.3 Examine sustained use of PPE	[Blue bar spanning all quarters from 2007 to 2018]																																													
10	8.3.1 Feasibility of procedure-driven focus	[Blue bar spanning all quarters from 2007 to 2018]																																													
11	8.3.1.2 Improve collaboration with HCW	[Blue bar spanning all quarters from 2007 to 2018]																																													

DRAFT

1417 IOM Recommendation # 9: Ensure Balance and Transparency of Standards-Setting Processes
1418 (Chap 5, p 165)

1419
1420 Federal agencies (e.g., FDA, NIOSH, OSHA) should use standards developed through a
1421 consensus-based transparent process that sets specific and clearly-defined limits regarding
1422 conflicts of interest (financial or other) and involves broad representation of all affected parties.

1423
1424 ***PPT Program Plan in response to IOM Recommendation # 9***

1425 9.1 Not in PPT Program domain, but in our purview


1426 9.2 Commit to standards setting bodies that use an open process for approvals, ie NFPA

DRAFT

2/5/2008

IOM Recommendation #9

PPT Program Response



DRAFT

Recommendation #9 Gantt Chart																																														
ID	Task Name	2007		2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018		
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3								
1	9.0 Ensure balance & transparency in standards	[Gantt bar spanning from Q3 2007 to Q3 2018]																																												
2	9.1 PPT Program oversight	[Gantt bar spanning from Q3 2007 to Q3 2018]																																												
3	9.2 Commit to open process	[Gantt bar spanning from Q3 2007 to Q3 2018]																																												

DRAFT

1439 IOM Recommendation # 10: Strengthen Pre-market Testing of PPE for Healthcare Workers
1440 (Chap 5, p 166)

1441
1442 FDA, NIOSH, and other relevant agencies and organizations should strengthen pre-market
1443 testing requirements for healthcare PPE by requiring field testing of PPE prior to approval and
1444 by reevaluating the FDA medical device classification for healthcare PPE. Testing requirements
1445 should use rigorous standards while also providing expeditious review of innovative approaches.
1446

1447 ***PPT Program Plan in response to IOM Recommendation # 10***

1448 10.1 Incorporating pre-market field testing requirements into NIOSH certification for respirators

1449 10.1.1 Can be done through rulemaking and/or approval processes.

1450 10.1.1.1 Describe the Part 84 proposal in 1987 and why it was rejected and potential
1451 logistical issues.

1452 10.1.1.2 Feasibility study should be conducted in collaboration with others to validate
1453 the need for PPE premarket testing (facilities, market share,etc.).

1454 10.2 Change FDA requirements so that all healthcare PPE undergoes pre-market testing prior to
1455 approval

1456 10.2.1 ** Pre-market testing—Immediate attention needs to be devoted in the next 6 to 12
1457 months to determining appropriate field testing parameters and methodologies for
1458 enhancing pre-market testing of healthcare PPE to focus the testing on efficacy
1459 against transmission of infectious disease and on enhancing wearability and other
1460 critical factors for use.

1461 10.3 Requiring certification of other types of PPE (e.g.,gowns, gloves).

1462 10.3.1 ** Only have authority to approve respirators.

1463 10.3.2 Neither have responsibility or authority to approve other types of PPE

1464 10.3.2.1 Have authority granted or assigned for other PPEs

1465 10.3.2.2 Congress grants approval for other types of PPEs


1466 10.3.2.3 Next best thing -- Provide scientific expertise to standard organizations' through
1467 another agency or NIOSH PPT participation.

1468 10.3.2.3.1 The PPT Program has several personnel who serve on various committees
1469 of Standards Organization (e.g., American National Standards Institute,
1470 International Standards Organization, etc.) to provide their valuable input.
1471 Additionally, PPE research work carried out by the PPT Program (i.e.,
1472 Homeland Emergency Response Operational and Equipment Systems -
1473 HEROES project) resulted in the development of a new American Society
1474 for Testing and Materials (ASTM) standard (ASTM F2668-07 Standard
1475 Practice for Determining the Physiological Responses of the Wearer to
1476 Protective Clothing Ensembles).

2/5/2008

IOM Recommendation #10

PPT Program Response



Recommendation #10 Gantt Chart																																															
ID	Task Name	2007		2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018			
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4								
1	10.0 Strengthen pre-market testing of PPE	[Gantt bar from Q1 2008 to Q4 2014]																																													
2	10.1 Incorporate pre-market testing NIOSH certification	[Gantt bar from Q1 2008 to Q4 2014]																																													
3	10.1.1 Rulemaking & approval process	[Gantt bar from Q1 2010 to Q4 2014]																																													
4	10.1.1.2 Examine 42 CFR Part 84	[Gantt bar from Q1 2008 to Q4 2010]																																													
5	10.1.1.3 Conduct feasibility to validate testing	[Gantt bar from Q1 2008 to Q4 2010]																																													
6	10.2 Change FDA requirements	[Gantt bar from Q1 2008 to Q4 2014]																																													
7	10.2.1 Pre-Market testing	[Gantt bar from Q1 2008 to Q4 2014]																																													
8	10.3 Require certification other PPE	[Gantt bar from Q1 2008 to Q4 2012]																																													
9	10.3.2 Decide who will certify	[Gantt bar from Q1 2008 to Q4 2012]																																													
10	10.3.2.1 Assign responsibility	[Gantt bar from Q1 2008 to Q4 2012]																																													
11	10.3.2.2 Congress grants authority	[Gantt bar from Q1 2008 to Q4 2012]																																													
12	10.3.2.3 Provide scientific expertise	[Gantt bar from Q1 2010 to Q4 2014]																																													

DRAFT

1482 IOM Recommendation # 11: Strengthen Post-market Evaluation of PPE for Healthcare Workers
1483 (Chap 5, p 166)

1484

1485 NIOSH, FDA, and other relevant agencies and organizations should support and strengthen
1486 adverse event reporting and post-market evaluation studies and surveillance regarding the
1487 effectiveness of PPE used by healthcare workers.

1488

1489 ***PPT Program Plan in response to IOM Recommendation # 11***

1490 11.1 Workplace effectiveness studies

1491 11.1.1 Continuous evaluation of effectiveness of PPT Program recommendations and
1492 guidance in healthcare in collaboration with NIOSH, CDC, and others.

1493 11.2 Head-to-head comparison studies of the efficacy of PPE to allow the employer and wearer
1494 to compare and evaluate products

1495 11.2.1 Efficacy studies related to PPT use and effectiveness should be conducted in
1496 collaboration with other NIOSH programs, CDC and NIAID.

1497 11.3 Adverse events reporting of problems with PPE use

1498 11.3.1 ** Except for respirators apprise DHHS

1499 11.3.2 Collaborate and share CPIP model, used for the respirator certification program, with
1500 others: Reference [L](#). The CPIP and QA models are being improved to be ISO 17025
1501 and ISO 9001 compliant. These efforts will improve portability.

1502 11.4 Worker health and medical surveillance where possible (e.g., infectivity rates).

1503 11.4.1 ** Near and long term opportunities exist for evaluation and surveillance projects.


1504 11.5 Continue current respirator PPE report auditing program

1505 11.5.1 Collaborate and share Quality Assurance (QA) module for respirators with other PPE
1506 post market evaluations: Reference [M](#). The CPIP and QA models are being improved
1507 to be ISO 17025 and ISO 9001 compliant. These efforts will improve portability.

2/5/2008

IOM Recommendation #11

PPT Program Response



		Recommendation #11 Gantt Chart																																															
ID	Task Name	2007		2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018					
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4		
1	11.0 Strengthen post-market eval. of PPE	[Gantt bar from Q3 2007 to Q4 2018]																																															
2	11.1 Workplace effectiveness studies	[Gantt bar from Q3 2007 to Q4 2018]																																															
3	11.1.2 Continuous evaluation of effectiveness of PPT Program	[Gantt bar from Q3 2007 to Q4 2018]																																															
4	11.2 Head-to-head comparison studies	[Gantt bar from Q3 2007 to Q4 2018]																																															
5	11.2.2 Conduct efficacy studies	[Gantt bar from Q3 2007 to Q4 2018]																																															
6	11.3 Adverse events reporting	[Gantt bar from Q3 2007 to Q4 2018]																																															
7	11.3.2 Collaborate & share CHIP model	[Gantt bar from Q3 2007 to Q4 2018]																																															
8	11.4 Worker health & medical surveillance	[Gantt bar from Q3 2007 to Q4 2018]																																															
9	11.4.1 Apprise DHHS	[Gantt bar from Q3 2007 to Q4 2018]																																															
10	11.5 Continue respirator report auditing program	[Gantt bar from Q3 2007 to Q4 2018]																																															
11	11.5.1 Collaborate & share QA model	[Gantt bar from Q3 2007 to Q4 2018]																																															

DRAFT

1512 IOM Recommendation # 12: Coordinate Efforts and Expand Resources for Research and
1513 Approval of PPE (Chap 5, p 166-167)

1514

1515 Congress should expand the resources provided to NIOSH to further research efforts on the next
1516 generation of PPE and to coordinate and expedite the approval of effective PPE. Efforts to
1517 coordinate PPE testing, certification, and approval across all relevant federal agencies should
1518 include developing evidence-based performance standards for all types of PPE for healthcare
1519 workers.

1520

1521 ***PPT Program Plan in response to IOM Recommendation # 12***

1522 12.1 Federal agency coordination—while each of the federal agencies has a distinct and vital
1523 role in ensuring the use of effective PPE, there is a strong need for a coordinated effort to
1524 ensure harmonization of requirements and to focus on coordinating the entire process from
1525 product design to use in the workplace. Many federal agencies in multiple departments
1526 (including the Departments of Defense, Health and Human Services, Homeland Security,
1527 and Labor) and the Consumer Product Safety Commission and the Environmental
1528 Protection Agency work to ensure worker safety and to approve, develop, and implement
1529 PPE.


1530 12.1.1 An assessment of current standards needs to be conducted to categorize existing PPE
1531 as it relates to current standards. PPT Program currently certifies performance of
1532 respirators, other PPE performance is assessed in accordance with consensus
1533 standards' test methods.

1534 12.1.1.1 PPT Program has limited infrastructure for PPT research, development and
1535 investigative testing beyond respirator issues. NPPTL is planning on expanding
1536 its capability in protective clothing research, development and investigative
1537 testing through training, additional personnel, and cooperative efforts with third
1538 party laboratories.

2/5/2008

IOM Recommendation #12

PPT Program Response




- 1544 ***PPT Program Plan in response to IOM Additional Issues # 13***
- 1545 13.1 Substantial gaps in knowledge regarding the design and implementation of PPE for family
- 1546 members and others during an influenza pandemic
- 1547 13.1.1 Describe the FDA Community use respirator and the science behind the decisions:
- 1548 Reference [N](#).
- 1549 13.1.2 Improved outreach approaches directed to healthcare users and facilities, including
- 1550 professional societies and labor representatives to disseminate PPT Program
- 1551 recommendations and guidance.
- 1552 13.1.3 Continuous evaluation of effectiveness of PPT Program recommendations and
- 1553 guidance in healthcare in collaboration with NIOSH, CDC, and others. Reference [O](#).
- 1554 13.2 Challenges include the benefits of minimizing or negating fit testing of respirators,
- 1555 protecting people with a wide range of face sizes (including children), protecting people
- 1556 with respiratory impairment.
- 1557 13.2.1 Describe future work to evaluate the frequency of fit testing: Reference [P](#).
- 1558 13.2.2 Examine PPT Program on anthropometrics: Reference [Q](#).
- 1559 13.3 Limited oversight of PPE sold in the retail marketplace
- 1560 13.3.1 Describe the current PPT Program procedures for quality assessment: Reference [M](#).
- 1561

2/5/2008

IOM Additional Issues #13

PPT Program Response



		Additional Issues Gantt Chart #13																																															
ID	Task Name	2007				2008				2009				2010				2011				2012				2013				2014				2015				2016				2017				2018			
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2				
1	Additional Issues	[Blue bar spanning all quarters from 2007 to 2018]																																															
2	13.1 Gaps in knowledge PPE family members	[Blue bar spanning all quarters from 2007 to 2018]																																															
3	13.1.1 FDA community & science behind decisions	[Blue bar spanning all quarters from 2007 to 2018]																																															
4	13.11.2 Improve outreach	[Blue bar spanning all quarters from 2007 to 2018]																																															
5	13.1.3 Continue evaluation PPE Program	[Blue bar spanning all quarters from 2007 to 2018]																																															
6	13.2 Challenges fit-testing, respiratory impairment	[Blue bar spanning all quarters from 2007 to 2018]																																															
7	13.2.1 Future work evaluate freq of fit testing	[Blue bar spanning all quarters from 2007 to 2018]																																															
8	13.2.2 Examine PPT anthropometrics program	[Blue bar spanning all quarters from 2007 to 2018]																																															
9	13.3 Oversight of PPE sold in retail marketplace	[Blue bar spanning all quarters from 2007 to 2018]																																															
10	13.3.1 Examine PPT prog Procedures quality assessment	[Blue bar spanning all quarters from 2007 to 2018]																																															

DRAFT

List of References

- A. Quad chart - Reusability of Filtering Facepiece Respirators
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6PT_FY07_QC.htm
- B. Quad Chart – Aerosol Generation by Cough
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/0026_FY07_QC.htm
- C. Workshop on Respiratory Protection for Airborne Infectious Agents (30 Nov – 1 Dec 04)
<http://www.cdc.gov/niosh/npptl/resources/pressrel/announcements/113004wkshp/questions.html>
- D. Commerce Business Daily – No Fit Test Respirator Workshop Nov 8, 2007
<http://www.cbd-net.com/index.php/search/show/18235875>
- E. Quad Chart – Penetration of Nanoparticles through NIOSH-approved Respirator Filters
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z1NT_FY07_QC.htm
- F. Quad Chart – Next Generation Structural Fire Fighting PPE Ensemble Project HEROES
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z4FY_FY07_QC.htm
- G. Quad Chart – Industrial PAPR Module
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6JC_FY07_QC.htm
- H. Quad Chart – New Sensor Technology Development and Integration for End of Service Life Indicators
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/000M_FY07_QC.htm
- I. Quad Chart – Total Inward Leakage (TIL)
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/00AY_FY07_QC.htm
- J. Quad Chart – Metabolic Evaluation of N95 Respirator Use with Surgical Masks
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6PV_FY07_QC.htm
- K. Quad Chart – Improved Criteria for Emergency Medical Protective Clothing
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z1NR_FY07_QC.htm
- L. Quad Chart – Certified Product Investigation Process (CPIP)
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/PP19_FY07_QC.htm
- M. Quad Chart – Quality Assurance Module
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z4FT_FY07_QC.htm
- N. U.S. FDA Respirators for Public Health Emergencies

- <http://www.fda.gov/consumer/updates/respirators061107.html>
- O. IOM Review of NIOSH Personal Protective Technology Program (PPT)
<http://www.iom.edu/CMS/3740/45683.aspx>
- P. Quad Chart – Frequency of Fit Testing
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z1NU_FY07_QC.htm
- Q. Quad Chart – Development of Computer-Aided Face-Fit Evaluation Methods
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/PP09_FY07_QC.htm
- R. NPPTL Facial Anthropometrics Research Roadmap Docket # NIOSH-111
<http://www.cdc.gov/niosh/review/public/111/>
- S. Certified Equipment List
<http://www.cdc.gov/niosh/npptl/topics/respirators/cel/>
- T. Whole Body Anthropometrics Research
www.cdc.gov/niosh/nas/traumainj/pdfs/TIAppendix5NAS03-07.pdf
- U. Elastic Textile Solution Pilot for Prototype Masks
<http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2D2008%2D49450/SynopsisP.html>
- V. Personal Protective Equipment (PPE) Effectiveness Study
<http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2D2008%2D49453/SynopsisP.html>